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 IMMUNE MODULATION OF THE MYCOBACTERIUM TUBERCULOSIS 
GRANULOMATOUS RESPONSE 
Kerry J. Welsh, M.P.H., B.S. 
Supervisory Professor: Jeffrey K. Actor, Ph.D. 
 
Tuberculosis (TB) remains a major public health burden.  The immunocompetant host 
responds to Mycobacterium tuberculosis (MTB) infection by the formation of granulomas, 
which initially prevent uncontrolled bacterial proliferation and dissemination.  However, 
increasing evidence suggests that granuloma formation promotes persistence of the 
organism by physically separating infected cells from effector lymphocytes and by inducing 
a state of non-replicating persistence in the bacilli, making them resistant to the action of 
antibiotics.  Additionally, immune-mediated tissue destruction likely facilitates disease 
transmission.  The granulomatous response is in part due to mycobacterial glycolipid 
antigens.  Therefore, studies were first undertaken to determine the innate mechanisms of 
mycobacterial cord factor trehalose-6’6-dimycolate (TDM) on granuloma formation.  
Investigations using knock-out mice suggest that TNF-α is involved in the initiation of the 
granulomatous response, complement factor C5a generates granuloma cohesiveness, and IL-
6 is necessary for maintenance of an established granulomatous responses.  Studies were 
next performed to determine the ability of lactoferrin to modulate the immune response and 
pathology to mycobacterial cord factor.  Lactoferrin is an iron-binding glycoprotein with 
immunomodulatory properties that decrease tissue damage and promote Th1 responses.  
Mice challenged with TDM and treated with lactoferrin had decreased size and numbers of 
granulomas at the peak of the granulomatous response, accompanied by increased IL-10 and 
TGF-β production.  Finally, the ability of lactoferrin to serve as a novel therapeutic for the 
 v 
treatment of TB was performed by aerosol challenging mice with MTB and treating them 
with lactoferrin added to the drinking water.  Mice given tap water had lung log10 CFUs of 
7.5 ± 0.3 at week 3 post-infection.  Lung CFUs were significantly decreased in mice given 
lactoferrin starting the day of infection (6.4 ± 0.7) and mice started therapeutically on 
lactoferrin at day 7 after established infection (6.5 ± 0.4).  Total lung inflammation in 
lactoferrin treated mice was significantly decreased, with fewer areas of macrophages, 
increased total lymphocytes, and increased numbers of CD4+ and CD8+ cells.  The lungs of 
lactoferrin treated mice had increased CD4+ IFN-γ+ cells and IL-17 producing cells on 
ELISpot analysis.  It is hypothesized that lactoferrin decreases bacterial burden during MTB 
infection by early induction of Th1 responses. 
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Epidemiology of tuberculosis 
 Tuberculosis (TB) is a major cause of infectious morbidity and mortality. TB 
causes approximately 1.8 million deaths annually, making it the leading cause of death 
due to bacterial infections worldwide [1].  Additionally, nearly one-third of the world’s 
population is latently infected with Mycobacterium tuberculosis (MTB) [1].  Over 95% 
of drug-susceptible MTB can be cured with a four drug regimen of isoniazid, rifampin, 
pyrazinamide, and ethambutol for two months followed by four additional months of 
isoniazid and rifampin [2].  However, it is estimated that only half of TB patients are 
effectively treated worldwide [1].  Treatment failure occurs because of noncompliance to 
the lengthy drug regimen, individual variation in response to antimicrobials against TB, 
and drug resistance [2].  With the exception of the potential role of the fluoroquinolones, 
there have been no new anti-TB drugs created since rifampin was introduced in the 
1960s [3].  Thus, agents with anti-mycobacterial activity or a beneficial effect when used 
in combination with the current anti-TB drugs are desperately needed.   
 TB infection is transmitted by aerosolization of MTB containing droplet nuclei 
produced from an infected person by coughing, sneezing, or forced respiratory activities 
[4].  Only about 30% of people exposed to TB bacilli get infected.  The risk factors for 
infection with TB in the United States include residing in the same household as a 
person infected with TB, living in an institutionalized setting with infectious TB cases, 
older age, immigration from a country with a high prevalence of TB, and living in an 
area with a high incidence of TB such as inner cities.  The initial infection is 
asymptomatic in most individuals.  However, a small percentage of infected persons (2 – 
23 %) will develop active TB disease [5].  The risk factors for progression to active TB 
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disease are malnutrition, certain gastrointestinal surgeries, young and old age, kidney 
disease, HIV infection, cancer, immunosuppressive therapies, and intravenous drug use 
[4]. 
 TB remains a public health burden despite the availability of antimicrobial 
chemotherapy.  The incidence of TB significantly decreased in the United States in the 
1800s before the advent of TB antibiotics [6].  The decline in TB incidence is possibly 
attributed to better housing and ventilation, improved nutrition, milk pasteurization, and 
use of sanatoriums to isolate infectious TB cases.  The development of streptomycin, 
para-aminosalicylic acid, and isoniazid combination therapy in the mid-20th century 
resulted in TB becoming a curable disease [7].  Anti-TB chemotherapy was significantly 
improved with the introduction of rifampin in a multi-drug regimen, which resulted in an 
even more rapid decline in TB incidence and mortality.  TB case number decreased 
approximately 6% annually from 1953 to 1985 [8].  However, TB incidence in the 
United States and other industrialized countries increased 20% from 1985 to 1992.  The 
resurgence of TB in developed countries is attributed to the HIV/AIDS epidemic, 
transmission of TB in institutionalized settings, a rise in immigration from areas with a 
high prevalence of TB, and a lack of funding and infrastructure for TB control programs 
[6].  The increase in TB incidence was reversed in 1993, with the number of TB cases in 
the United States decreasing by approximately 5-7% per year from 1993-1997. 
 Multidrug resistant (MDR)-TB emerged with the increase of TB incidence in the 
United States [8].  Poor patient adherence to treatment regimens and incorrect or erratic 
treatment caused by a number of clinical and social factors contributed to the 
development of drug-resistant TB [9].  Thus, new anti-TB agents are needed for 
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treatment of MDR-TB and to improve current treatment options to allow for shorter and 
more intermittent therapy.   
 
M. tuberculosis induced pathology   
The hallmark of MTB pathology in the immunocompetant adult is the caseating 
granuloma, which consists of central infected macrophages that may differentiate into 
foamy macrophages, epithelioid cells, and Langhan’s giant cells (Figure 1.1A) [10].  The 
majority of cells in the granuloma are positive for CD68 and CD4 [11].  A layer of 
fibrous surrounds the infected macrophages, which isolates the organism and prevents 
bacterial dissemination.  The periphery of the granuloma consists of lymphocytes that 
are a mixture of CD4+, CD8+, and CD20+ cells [11].  Occasional T-regulatory cells are 
observed in the lymphocytic portion of the granuloma [11, 12].  The fibrotic portion of 
the granuloma causes physical partitioning of infected cells from effector lymphocytes 
that are able to kill infected cells and inhibits the penetration of antibiotics [10].  
 The majority of granulomas persist for the life of the individual without causing active 
TB disease.  However, approximately 2 - 23% of infected individuals develop 
reactivation of infection [5].  These post-primary (secondary) TB cases cause the 
majority of TB disease and nearly all transmission of the bacilli [13].  Post-primary TB 
is characterized histologically as a lipid pneumonia, with foamy macrophages in alveoli 
and lymphocytes in the alveolar walls and alveoli (Figure 1.1B) [11, 14].  The majority 
of lymphocytes in lipid pneumonia are positive for CD8, with relatively fewer CD4+ 
lymphocytes compared to other tissue manifestations of TB.  It is hypothesized  
that there is an accumulation of mycobacterial antigens, possibly glycolipids, that 
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 Figure 1.1. Tuberculosis induced pathology. A. Typical caseating granuloma of 
primary TB consists of central necrosis flanked by foamy and epitheliod 
macrophages. Occasional Langhan’s giant cells are noted. The periphery of the 
granuloma consists of lymphocytes. B. The lipid pneumonia of early post-primary 
TB is characterized by alveoli filled with foamy macrophages. Lymphocytes are 
found in the alveoli and alveolar walls. C. Cavitary lesions consist of a wall of 
macrophages and necrotic debris. Abundant fibrosis and lymphocytes are noted 
surrounding the cavity wall.  Welsh KJ, et al. Clin Devel Immuno. 2011 [11]. 
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initiates tissue necrosis and the formation of cavities.  
Cavitary lesions, the hallmark of active TB disease, likely result from abrupt 
necrosis of the lipid pneumonia [11, 14].  The wall of the cavity consists of necrotic 
tissue and foamy macrophages (Figure 1.1C).  Numerous lymphocytes line the wall of 
the cavity and consist of CD4+, CD8+, CD20+, as well as numerous T-regulatory cells 
[11].  The damage to the lung resulting from TB-induced immunopathology causes a 
productive cough, producing infectious aerosols that may infect a new host.  Modulation 
of the inflammatory pathology will likely facilitate improved response to antimicrobials, 
limit transmission of the disease, and decrease morbidity [15]. 
 
The immune response to M. tuberculosis 
MTB infection is initiated by inhalation of TB bacilli that are deposited in the alveoli, 
which become phagocytosed by alveolar macrophages [10].  The macrophages produce 
tumor necrosis factor-alpha (TNF-α) and chemokines that recruit systemic monocytes, 
forming the nascent granuloma (Figure 1.2).  The acquired immune response develops 
after migration of dendritic cells to the draining lymph nodes.  Dendritic cell production 
of IL-12 initiates the development of interferon-gamma (IFN-γ) producing Th1 cells, 
while the synthesis of interleukin (IL)-6 and transforming growth factor-beta (TGF-β) 
promotes the development of Th17 cells [16].  Th1 and Th17 cell populations migrate to 
the lung in response to chemokine gradients.  The induction of the specific immune 
response correlates with control of MTB infection.  This section reviews the  
cell types and cytokines essential for immunity to MTB.   
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Figure 1.2. Schematic depicting the major immunologic events leading to 
granuloma formation.  Infection with MTB initiates with the deposition of bacilli into 
the alveoli. MTB are phagocytosed by alveolar macrophages that secrete cytokines such 
as TNF-α and chemokines  that recruit systemic monocytes to form the nascent 
granuloma. The adaptive immune response begins when infected dendritic cells migrate 
to the draining lymph nodes of the lung. Dendritic cell production of IL-12 polarizes 
naive T-cells to the Th1 phenotype, while TGF-β and IL-6 promote Th17 cells. 
Lymphocytes migrate to the lung to form the mature granuloma. 
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Macrophages 
 The first cells to encounter TB bacilli are likely alveolar macrophages [17]. 
Macrophages phagocytose mycobacteria using mannose receptors, complement 
receptors, and scavenger receptors [18-20].  The phagosome in most infections 
undergoes maturation processes that result in fusion with lysosomes, inducing organelle 
acidification and the activation of lytic enzymes that result in bacterial death.  However, 
MTB is able to prevent phagolysosomal fusion, giving the organism the ability to 
survive within macrophages [21].  The mechanism of MTB inhibition of 
phagolysosomal fusion may be due to mycobacterial cell wall products, such as 
sulfatides and glycolipids [22, 23]. 
 Macrophages have mechanisms to control proliferation of MTB.  Macrophage 
activation by IFN-γ, and to a lesser extent by TNF-α, causes inducible nitric oxide 
synthetase (iNOS) to produce NO and reactive nitrogen intermediates using arginine as 
the substrate [21].  Numerous studies have demonstrated the critical importance of 
nitrogen oxides in protection against MTB, both in vitro and in vivo [24, 25].  
Furthermore, macrophages play a role in antigen presentation and production of IL-12 
that are critical for the generation of the adaptive immune response [26, 27]. 
 While macrophages possess the ability to kill MTB, there is some evidence that 
macrophages contribute to the chronic nature of MTB infection.  Macrophages in TB 
infection may become foam cells, possibly by dysregulation of host lipid metabolism 
[17].  It was recently reported that foamy macrophages (FM) positive for the dendritic 
cell (DC) marker DEC-205 collect in the alveoli along with CD8+ lymphocytes in both 
the alveolar walls and alveoli in humans with early post-primary TB [11].  Ordway et al. 
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[28] demonstrated that the FM in mouse granulomas stained positive for DEC-205.  The 
DEC-205 positive FM in mice had additional markers of DCs such as CD40, CD11c, 
and major histocompatibility complex II (MHC II) in addition to high levels of 
antiapoptotic markers.  The importance of FM expressing DC markers has not been 
elucidated.  However, DCs infected with MTB can harbor the bacilli for long periods of 
time and lack efficient mechanisms for eliminating MTB [29-31].  FM with DC 
characteristics may thus provide a favorable environment for the growth of MTB.  
Furthermore, FM may suppress the cell-mediated immunity that is necessary to 
eliminate MTB.  For example, FM produce high amounts of TGF-β that can induce 
apoptosis of immune cells [32].  Additionally, FM synthesize high levels of iNOS, 
which may cause suppression of T-cells [33].  Therefore, FM may cause local immune 
suppression that contributes to inability of the immune system to clear post-primary TB.      
 
Dendritic cells 
 DCs are another innate immune system cell essential for protection against MTB.  
DCs are considered permissive for MTB growth because they harbor the bacilli for 
extended periods of time and do not appear to be capable of killing MTB, despite 
activation with IFN-γ [29-31].  However, DCs are essential for host defense against 
MTB because mice lacking CD11c cells were less able to control MTB growth, possibly 
by delayed CD4+ T-cell activation [34]. 
 The major function of DCs is to promote T-cell responses following infection 
with MTB [35].  DCs that become infected with MTB or have phagocytosed MTB 
antigen become activated and produce IL-12p40, enabling the DC to respond to 
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chemokines such as CCL19 and CCL21 that allow the DC to migrate to the draining 
lymph nodes [36].  DC production of IL-12 to naive T-cells polarizes T-cells to the Th1 
phenotype, which are essential for bacterial control.  DCs also synthesize IL-6 and TGF-
β that generate Th17 cells that play a number of important roles in the immune response 
against MTB [36]. 
 
T-cells 
Cell mediated immunity is essential for host defense again MTB.  This is due to 
the fact that MTB is an intracellular organism and thus effector T-cells are needed to 
control bacterial growth.  Both CD4+ and CD8+ T-cells become activated in the 
draining lymph nodes of the lung during week one of infection in the mouse model of 
MTB; these cells migrate to the lung between two and four weeks post-challenge [37, 
38].  A significant portion of these cells are positive for CD69, suggesting that activated 
T-cells are migrating to active sites of infection [21]. 
CD4+ T-cells are critical to the outcome of MTB infection. CD4+ T-cells 
respond to antigen presented on MHC II, which present exogenous antigen that was 
processed in phagolysosomes [39].  Studies in mice using knock-out mice, adoptive 
transfer, and antibody neutralization of CD4+ cells all demonstrate that CD4+ T-cells 
are an absolute requirement for infection control [40-44].  Another example of the 
importance of the CD4+ T-cell response can be found in humans with advanced HIV, 
who develop disseminated mycobacterial infections when CD4+ T-cells reach low levels 
[45].  CD4+ T-cells also promote the development of CD8+ cytotoxic T-cells, which are 
also important for control of disease pathology [46].  There are four subtypes of CD4+ 
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T-cells that play various roles during MTB infection; these are T-cell helper type 1 
(Th1), Th2, Th17, and T-regulatory (Treg) cells. 
1. Th1 phenotype.  Control of MTB infection is strongly dependent on the 
induction of a Th1 immune response.  The Th1 response is characterized by populations 
of CD4+ T-cells that produce IFN-γ upon activation [47].  Th1 responses are initiated by 
innate immune cell production of IL-12 during antigen presentation to naive T-cells.  
The importance of IL-12 is demonstrated by IL-12p40 deficient mice that have markedly 
increased bacterial burdens and decreased survival time when infected with MTB [48].  
The IL-12 induced generation of CD4+ IFN-γ producing cells are critical for the host 
defense against MTB.  IFN-γ production by Th1 CD4+ cells causes activation of 
macrophages, resulting in phagosome acidification and production of reactive nitrogen 
species capable of killing MTB [46].  IFN-γ additionally promotes upregulation of MHC 
II expression that further induces antigen presentation and T-cell stimulation [39, 49].  
The importance of IFN-γ production is highlighted by IFN-γ knock-out mice that are 
extremely susceptible to MTB [50, 51].  Additionally, humans with mutations in IFN-γ 
or its receptor are likely to have serious mycobacterial infections [52].  Therefore, it is 
critical that immunomodulatory agents useful in control of MTB infection produce a 
strong Th1 response. 
2. Th2 phenotype.  Th2 immune responses are characterized by the production of 
cytokines such as IL-4 and IL-10.  The role of Th2 responses in TB infection is unclear.  
The increase in bacterial burden that occurs after 3 weeks in mice challenged with a high 
dose of MTB is accompanied by increased IL-4 [53].  Additionally, IL-4 knock-out mice 
were more resistant to MTB infection [21].  However, IL-10 deficient mice do not have 
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increased resistance in comparison to wild-type mice [54].   Detection of Th2 responses 
in humans is difficult [21].  It has been reported in humans that decreased Th1 responses, 
but not increased Th2 responses, are found in PBMCs from TB patients [55-57].  Thus, 
elevated Th2 responses are not likely associated with TB in humans.     
3. Th17 phenotype.  While Th1 responses are clearly necessary for host defense 
against MTB, this immune response alone is not sufficient [21].  Th17 cells are a 
recently discovered T-cell subset with a number of regulatory functions.  Th17 responses 
are initiated by TGF-β in combination with IL-6, and further expanded by IL-23 [58].  
Th17 cells synthesize characteristic cytokines IL-17A, IL-17F, IL-21, and IL-22 that 
promote upregulation of other proinflammatory mediators including chemokines, IL-6, 
and GM-CSF [59-63].  A number of investigations have demonstrated that Th17 cells 
may play an important role in the immune response against MTB [64-66].  Enhancement 
of IL-17 responses early in MTB infection by use of an IL-23 synthesizing adenovirus 
resulted in reduced lung pathology and decreased bacterial burden [67].  Additionally, 
Th17 cells from humans recently infected with TB had the phenotypic markers of long-
lived central memory cells and were distinct from Th1 effector memory cells [68], 
suggesting that Th17 cells may give long-lasting immunity to TB.    
4. Treg cells.  Treg cells, identified by Foxp3 expression, are considered essential 
for preventing autoimmunity [69].  However, the function of Tregs in infectious diseases 
including MTB is incompletely understood.  Tregs synthesize suppressive cytokines 
such as IL-10 and TGF-β that limit excess inflammation, but may prevent clearance of 
pathogens [70].  Treg cells in the peripheral blood decrease in newly infected contacts of 
patients with active TB disease, possibly due to their migration to the infected lung [71].  
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Tregs accumulate in sites of disease and in blood as the infection progresses [12, 72-74].  
Differential Foxp3 expression in PBMCs differentiated active TB from latent TB 
infection [75].  Foxp3+ cells were found to decrease T-cell responses to mycobacterial 
antigens in human patients [76].  Neutralization of Treg cells during mouse models of 
infection enhanced elimination of MTB [77, 78], providing further support that Treg 
cells have a negative impact on MTB infection.  Another investigation showed that small 
numbers of Tregs specific for MTB prevent the aggregation of CD4+ and CD8+ T-cells 
in infected mouse lungs [79].  Finally, it was recently shown that human cavitary lesions, 
lesions that rarely spontaneously heal, contained a higher percentage of Tregs compared 
to other pathological manifestations of TB [11]. 
CD8 T-cells.  CD8+ T-cells also potentially play a role in MTB infection.  These 
cells recognize antigen presented on MHC I molecules, and may produce IFN-γ when 
activated.  MTB antigens are thought to gain access to the MHC I molecules by pores in 
the vesicular membrane of the phagosome or an alternate processing pathway for MHC I 
[80].  CD8+ lymphocytes can be found in granulomas at approximately the same 
frequency as CD4+ cells [11].  CD8+ T-cells may directly lyse MTB-infected cells, and 
have been reported to potentially overcome the absence of CD4+ T-cells [43, 81, 82].  
The mechanisms of CD8+ cell dependent lysis are perforin and granulysin [83-85].  
However, mice lacking CD8+ T-cells have higher bacterial burdens, but generate normal 
granulomas and ultimately control the infection [86].      
 
Soluble factors 
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 A number of protein mediators such as the complement system and cytokines 
play essential roles in during bacterial infections.  Cytokines function as signaling 
mediators between cells and are essential regulators of all aspects of immunity.  The 
cytokines central to the adaptive immune response have been discussed elsewhere in this 
review.  This section will discuss the functions of the complement system and the 
cytokines TNF-α and IL-6. 
 The complement system.  The complement system plays a central role in innate 
immunity and the initiation of adaptive immunity [87].  The three major pathways of 
complement are the classical, alternative, and lectin pathways.  The classical pathway 
begins when certain subclasses of IgG or IgM bind to antigen.  C1q binding to Fc sites 
induces C1r to activate C1s.  C1s cleaves C4 and C2, which forms the classical pathway 
C3 convertase (C4b2a).  The classical C3 convertase cleaves C3, generating the C5 
convertase (C4b2a3b) that cleaves C5.  The result may be lysis of cells by the deposition 
of C5b-9 on the surface of cells, inflammation by C3a and C5a-induced chemotaxis of 
leukocytes, or opsonization and phagocytosis of cells mediated by C3b.  The lectin 
pathway is similar to the classical pathway, except that it starts with the binding of 
mannose-binding lectin to microbial surfaces that induces proteases to cleave C4 and C2.  
The alternate pathway is initiated when C3 undergoes spontaneous auto-cleavage to 
C3b.  C3b binds to factor B and properdin to form the C3 convertase (C3bBb).  The C3 
convertase enzymatically cleaves additional C3 to form the C5 convertase (C3bBbC3b), 
which cleaves C5 [87].   
 New evidence suggests that complement plays a major role in the induction of T-
cell responses in addition to its clear role in innate and humoral immunity [88].  The 
 15 
binding of complement factors to the C3a and C5a receptors promotes the migration of 
antigen presenting cells to areas of infection, where they present antigen to T-cells and 
modulate IL-12 production [89-91].  Binding of immune complexes to the C1q receptor 
on T-cells promotes T-cell activation with production of TNF-α and IFN-γ [92].  C5a 
binding to the C5a receptor on T-cells directs their migration to sites of inflammation 
[93].  Both CD4+ and CD8+ T-cells responses in C3 deficient mice are decreased in 
viral infection models [94-96].  The precise role of complement factors in immunity and 
pathology during MTB infection is unclear.  It was reported that mice deficient in 
complement C5 have decreased survival, increased inflammation, and decreased 
macrophage cytokine production [97, 98].  The studies presented here examine the role 
of C5a in the early initiation and maintenance of the granulomatous response.   
 TNF-α.  TNF-α is a proinflammatory cytokine synthesized by dendritic cells, 
macrophages, and T-cells that plays a critical role in the regulation of acute and chronic 
granulomas [99].  Neutralization of TNF-α or mice with a deficiency of TNF-α or its 
receptor rapidly succumb to MTB infection, have markedly increased bacterial loads, 
and a dysregulated granulomatous response [100-102].  The mechanism of TNF-α in 
host resistance to MTB is possibly due to its ability to partially activate macrophages, 
increasing their cytotoxicity, and facilitating the interactions between macrophages and 
T-cells that are necessary to generate granulomas [103]. 
 However, there is increasing evidence that the granulomatous response promotes 
a survival advantage to MTB in the host and that the organism possesses specific 
mechanisms to drive TNF-α production [15].  Mycobacterial cell walls contain 
glycolipids, such as trehalose dimycolate, that induce TNF-α and drive granuloma 
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formation [99].  MTB may also promote TNF-α production by direct interference with 
intracellular signaling.  A MTB mutant deficient in the adenylate cyclase Rv0386 was 
characterized by reduced cAMP after infection, accompanied by decreased protein 
kinase A and CREB activation, and ultimately decreased TNF-α synthesis by infected 
macrophages [104].  The mutant MTB had poor survival in a mouse infection model and 
decreased lung pathology.  It has thus been proposed that the induction of excessive 
TNF-α production by MTB is a component of the virulence of the organism [15].  
 IL-6.  The role of IL-6 in the host defense against MTB is unclear.  This cytokine 
is produced by fibroblasts, macrophages, B-cells, and T-cells.  IL-6 possibly interferes 
with IFN-γ signaling and increases IL-4 production, both of which may inhibit protective 
Th1 responses [105].  Production of IL-6 by BCG infected macrophages inhibited T-cell 
responses [106].  However, IL-6 -/- mice infected with MTB have produced mixed 
results.  Intravenous challenge MTB was lethal for IL-6 knock-out mice [107]; however, 
aerosol challenge of the IL-6 -/- mice had later production of IFN-γ but were ultimately 
able to control the infection [105].  Thus, IL-6 may play a role in the immune response 
against MTB, but its precise function remains to be determined. 
 
The role of trehalose 6,6’-dimycolate on MTB pathogenesis 
 Mycobacterial cell walls possess abundant lipid, accounting for approximately 
half of the dry weight of MTB [108].  The lipid content of MTB includes mycolic acids, 
which consist of long chains of fatty acids with 78 – 90 carbons [109].  Trehalose 6,6’-
dimycolate (TDM) is the most abundant glycolipid on the surface of MTB [13].  TDM, 
also referred to as mycobacterial cord factor, was identified due to the ability of MTB to 
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form serpentine cords.  TDM structurally consists of two trehalose molecules, each with 
a mycolic acid chain with 60 – 90 carbons (Figure 1.3) [13].  The biologic activity of 
TDM depends on its presentation [110].  TDM mixed in an aqueous solution forms 
micelles that are non-toxic; TDM on the surface of MTB is hypothesized to exist in the 
micelle form.  In contrast, TDM monolayers formed on hydrophobic surfaces, such as 
oil-water interfaces, are toxic in microgram quantities [110].  TDM is thought to play a 
number of important roles in MTB pathogenesis, including virulence and granuloma 
formation. 
 TDM is hypothesized to contribute to the virulence of MTB.  Higher levels of 
TDM are found on the surface of virulent MTB than avirulent organisms [111].  
Extraction of TDM from mycobacteria decreases the organism’s ability to survive in 
both macrophages and mice; reconstituting purified TDM largely restores the organisms’ 
survival in macrophages [112-114].  Decreased MTB ability to produce excess TDM is 
accompanied by a decrease in virulence [115, 116].  Furthermore, alterations in the 
structure of TDM such as absence of the cyclopropane rings results in decreased 
bacterial growth in macrophages and mice [117].  Removal of TDM from the surface of 
MTB resulted in enhanced macrophage ability to undergo phagosome acidification and 
fusion with lysosomes [112].  Additionally, surface TDM decreases macrophage 
expression of MHC II, CD40, CD80, CD86, and CD1d, markers that are essential for 
antigen presentation and stimulation of T-cells [23]. 
TDM is likely involved in induction of the granulomatous response during MTB 
infection.  Administration of a single dose of TDM in emulsion form induces foreign  
 
 18 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ishikawa, E., et al. JEM. 2009; v206: 2879‐88. 
 
Figure 1.3. Structure of trehalose-6,6’-dimycolate (TDM). TDM is 
composed to two molecules of trehalose each with a mycolate attached. The 
structure contains double  bonds  and cyclopropane molecules that are 
necessary for its activity [123].  
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body lung granulomas; these granulomas peak in size and number at one week and 
completely resolve two-weeks post-challenge [80].  This granulomatous response is 
accompanied by pro-inflammatory cytokine production including TNF-α, IL-6, IL-1β, 
IFN-γ, IL-12, as well as chemokines [118, 119].  TDM can additionally promote 
hypersensitive granulomatous response by TDM challenging mice that have been 
immunized with TDM and protein [80, 120, 121].  Hypersensitive granulomas in 
response to TDM are characterized by large, destructive granulomas that have a 
significant lymphocyte composition.  The hypersensitive response is accompanied by 
synthesis of Th1 cytokines such as IFN-γ and IL-2.   The hypersensitive granulomatous 
response was demonstrated to be transferable by CD3+ TDM immunized cells; CD4+ 
cells were later determined to be responsible [120, 121].  TDM has also been implicated 
in the induction of caseating granulomas [110].    
 It has long been established that the proinflammatory responses to TDM are 
mediated by macrophages [122].  However, receptors for binding and signaling for TDM 
were only recently discovered.  Bowdish et al [122] reported that the macrophage 
scavenger receptor MARCO forms a complex with TLR2 and CD14 that recognizes 
TDM-coated microspheres.  Other investigators showed that macrophage inducible C-
type lectin (Mincle) bound TDM coated onto plates [123, 124].  Mincle response to 
TDM requires the Fc receptor γ chain (FcRγ) and Sky-Card9-Bcl10-Malt1 signaling 
pathway [125].   
 Glycolipid-specific T-cells are induced in mycobacterial infected humans and 
guinea pigs [126].  However, antigen presentation occurs via CD1 rather than MHC I or 
II.  CD1 molecules present hydrophobic ligands [80].  Humans possess five CD1 family 
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members, divided into group 1 (CD1a, CD1b, CD1c) and group 2 (CD1d, CD1e).  Mice, 
however, have only two CD1 genes (CD1d1 and CD1d2) [80].  Therefore, it is difficult 
to compare studies of humans and mice on CD1 presentation of glycolipids.  Murine 
macrophages upregulate CD1d1 after stimulation with TDM [127], but TDM-specific 
CD1d T-cells have not been identified in mice.  However, it was demonstrated that mice 
lacking CD1d (CD1d -/-) have dysregulated acute granulomatous response to TDM 
[128].  In the hypersensitive granuloma model, CD1d -/- mice had less destructive lung 
lesions, loosely organized CD3+ lymphocytes, and increased proinflammatory cytokines 
[129].  Thus, the precise role of CD1 in the presentation of TDM is still being delineated.  
 It is well established that TDM induces a number of immunological mediators; 
however, the specific cytokines that necessary for granuloma formation are unknown.  
Studies from our laboratory demonstrated that regulation of corticosterone in the lung by 
11beta-hydroxysteroid dehydrogenases modulates the progression TDM-induced 
granuloma formation [130].  The work in this thesis explores the role of complement 
factor C5a, TNF-α, and IL-6 in the initiation and maintenance of TDM-induced 
granuloma, and the ability of lactoferrin to modulate this granulomatous response.           
  
Modulation of TB-induced immunopathology as an adjuvant to antimicrobial 
chemotherapy   
Granuloma formation is considered a favorable response that prevents bacterial 
replication and dissemination to other organ systems.  However, MTB localized within 
granulomas are protected from sterilizing antimicrobials and immune-mediated killing 
[15].  MTB within granulomas undergo conversion to a state of non-replicating 
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persistence that includes changes in biosynthetic pathways and decreased replication 
[131, 132].  The action of antibiotics requires bacilli that are actively replicating for 
effectiveness and thus are unable to eliminate the dormant MTB within granulomas.  
Additionally, reduction of lung inflammatory pathology may facilitate antibiotic 
penetration into infected tissue, thereby inducing a faster response to antibiotics [15, 
133].  Indeed, MTB mutants that lack the ability to induce granulomas have significantly 
reduced survival in mice and less lung pathology [104].  Additionally, it is hypothesized 
that the inflammatory response to MTB is responsible for disease transmission; 
modulation of the immune response may limit dissemination of the bacilli to new hosts 
[15, 17, 134].  
Immunomodulators combined with TB antibiotics has generated favorable results 
in human clinical studies.  One clinical trial combined etanercept, a soluble TNF-α 
receptor, with standard TB chemotherapy in HIV patients with TB and reported 
significantly increased bacterial clearance and improved chest x-ray results in the 
patients treated with the combination therapy [135].  Another study explored high-dose 
corticosteroids with anti-TB drugs in patients co-infected with HIV and TB [136].  
Sputum culture conversion was significantly increased in the patients given prednisolone 
compared to patients given standard TB chemotherapy alone.  The studies in this thesis 
use lactoferrin as an immunomodulator during MTB infection; lactoferrin has numerous 
advantages over other available immunomodulators because it does not suppress the 
immune system and has a proven safety record in a number of animal studies and human 
clinical trials [137-139]. 
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Lactoferrin as an immune modulator 
New evidence identifies lactoferrin as an immune response modulator to a 
number of infectious and inflammatory stimuli [140, 141].  Lactoferrin is member of the 
transferrin family and is found in epithelial secretions as well as in the granules of 
neutrophils [140].  The serum concentration of lactoferrin is normally low, at less than 1 
µg/ml, but markedly increases during injury and inflammation [142, 143].  Lactoferrin 
receptors are found on many different immune cells, such as macrophages, dendritic 
cells, and T-cells [144-146].  Reported immunomodulatory properties of lactoferrin 
include macrophage activation, promoting polymorphonuclear cell phagocytosis, 
enhancement of T- and B-cell maturation, and augmentation of antigen specific immune 
responses [147-149].   
 
Lactoferrin modulation of innate immunity 
Lactoferrin modulates the activity of innate antigen presenting cells (APCs), which 
in turn have the potential to alter T-cell responses.  APCs, including dendritic cells, 
process and present antigen to naive CD4+ T-cells using MHC II along with co-
stimulatory molecules such as CD40, CD80, and CD86 [39, 150].  APC production of 
IL-12 promotes the development of naive CD4+ T-cells to a Th1 phenotype [26, 151].  
Thus, alteration of APC cytokine production and surface molecule expression has the 
potential to enhance the development of the acquired immune response. 
Lactoferrin enhances dendritic cell and macrophage function as APCs to activate 
CD4+ T-cells.  Macrophages stimulated with IFN-γ and infected with mycobacteria have 
decreased MHC II expression [152-154].  Lactoferrin added to activated macrophages 
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infected with BCG significantly increased expression of MHC II [155, 156].  Lactoferrin 
increased the CD86:CD80 ratio in dendritic cells and macrophages infected with BCG 
[155, 157], suggesting that APCs treated with lactoferrin are better at promoting 
activation of T-cells during antigen presentation [158, 159].  Indeed, dendritic cells and 
macrophages infected with BCG and incubated with lactoferrin had significantly 
enhanced IFN-γ production from both CD3+ and CD4+ cells in comparison to APCs 
cultured in the absence of lactoferrin [155, 157].  Additionally, lactoferrin increased 
expression of CD40 on the mouse macrophage cell line RAW 264.7 as well as peritoneal 
macrophages [160].  Immature human dendritic cells cultured with recombinant human 
lactoferrin increased human leukocyte antigen II, CD80, CD86, CD83, in addition to 
chemokine receptors necessary for migration to draining lymph nodes [161].  
IL-12 is essential for the promotion of the Th1 cytokine IFN-γ, both in the 
maturation of naive T-cells to the Th1 phenotype and in maximizing production of IFN-γ 
from established Th1 effector and memory cells [162, 163].   Injection of lactoferrin 
intraperitoneally into mice increased production of IL-12 from peritoneal macrophages 
recovered from the mice [147].  Other investigators have shown that lactoferrin 
administered orally increases IL-12p40 expression, accompanied by decreased 
expression of IL-10 [164].  Indeed, macrophages infected with BCG and treated with 
lactoferrin demonstrated a significantly increased ratio of IL-12 to IL-10, a cytokine that 
inhibits the action of IL-12 [147].  Furthermore, lactoferrin increased TGF-β production 
from dendritic cells and macrophages infected with BCG [155, 157].  TGF-β in 
combination with IL-6 promotes the generation of Th17 responses [59], which may play 
an important role in protection against MTB [64, 68].  In summary, these studies indicate 
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that lactoferrin strongly modulates APC function.  The impact of lactoferrin on innate 
cell function involved in the initial interaction with microbes gives it potential to 
enhance the generation of the adaptive immune response, with clear mechanisms to 
support its use as an adjunct therapeutic for the treatment of TB. 
 
Lactoferrin modulation of the acquired immune response 
Lactoferrin has a number of direct effects on T-cell responses in addition to 
modulation of innate responses.  CD4+ and CD8+ T-cells possess receptors for 
lactoferrin [165].  Lactoferrin affects the levels of co-stimulatory surface molecules that 
impact T-cell function, suggesting that lactoferrin modulates T-cell response to antigen.  
The maturation of double negative mouse T-cells preferentially towards CD4+ T-cells is 
enhanced by human lactoferrin, possibly through Erk2 and p56lck to activate the MAP 
kinase pathway [166, 167].  Administration of oral lactoferrin to mice increased CD4+ 
and γδ T-cells as well as total circulating granulocytes [164].  Lactoferrin increased 
expression of leukocyte function associated antigen, an adhesion molecule involved in 
cell-to-cell contact on T-cells [168].  Expression of the human T-cell ζ-chain, a 
component of the CD3 T-cell receptor complex involved in signaling, was enhanced by 
lactoferrin [169]. 
Lactoferrin can polarize naive T-cells to either Th1 or Th2 phenotypes, depending on 
the cytokine environment and antigen.  Studies demonstrate that lactoferrin can augment 
production of cytokines needed for the development of a Th1 response, with increase of 
the delayed-type hypersensitivity (DTH) response to BCG, sheep red blood cells, and 
ovalbumin [147, 170, 171].  Transgenic mice expressing human lactoferrin and infected 
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with Staphylococcus aureus had increased IFN-γ and TNF-α, along with decreased IL-
10 and IL-5 [172].  Oral administration of lactoferrin increased Th1 T-cell responses, 
indicated by enhanced levels of IFN-γ, in both naive and tumor-harboring mice [173, 
174].  The IL-12:IL-10 ratio was increased by lactoferrin in LPS stimulated splenocytes 
[175].  Furthermore, chronic hepatitis C virus elimination was augmented by the 
combination of lactoferrin and interferon therapy, possibly by increasing Th1 responses 
[176].  In contrast, lactoferrin increased IL-10 and decreased IFN-γ in an infection model 
of Toxoplasma gondii, indicating the enhancement of Th2 responses [177].  The effects 
of lactoferrin on Th17 cells are currently unknown. 
Lactoferrin additionally alters B-cell responses.  Immature B-cell incubation with 
lactoferrin increased their proliferation in response to antigen-specific T-cells [149].  
Lactoferrin augments maturation of immature mouse B-cells, indicated by increased 
expression of the complement 3 receptor and IgD [149].  Lactoferrin increases mouse 
Peyer’s patches production of IgG and IgA [178].  Mice treated with lactoferrin had 
increased levels of IgG in both the serum and intestine [179].  Additionally, lactoferrin 
increases antibody-forming cells and humoral responses to sheep red blood cells in mice 
treated with methotrexate and cyclophosphamide [180-182].  Taken together, these 
investigations suggest that lactoferrin directly affects B-cells, and enhances their 
function as APCs to generate T-cell responses.    
Essential for the studies performed here, lactoferrin decreases immune-mediated 
tissue damage.  For example, mice administered lactoferrin had decreased mortality and 
reduced destruction of gut tissue following LPS injection [183].  Lactoferrin also 
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decreased tissue damage in mouse models of rheumatoid arthritis and inflammatory 
bowel disease [184-186]. 
 
Summary of Thesis 
 This thesis will explore the cytokine mechanisms of TDM-induced granulomas 
and the ability of lactoferrin to modulate TB-induced immunopathology.  Initial studies 
examined the role of TNF-α, complement factor C5a, and IL-6 in the initiation and 
maintenance of TDM-induced granulomas (Chapter 2).  Studies were next undertaken to 
explore the ability of lactoferrin to modulate immune-induced pathology to 
mycobacterial antigen (Chapter 3).  Finally, the ability of lactoferrin to serve as an 
adjuvant therapeutic for TB was evaluated by treating MTB infected mice orally with 
lactoferrin (Chapter 4).  The mechanisms of lactoferrin-mediated immune modulation 
during MTB infection are discussed. 
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Chapter Two 
The role of TNF-α , complement C5a, and IL-6 in the induction and maintenance of 
mycobacterial cord factor trehalose 6,6’-dimycolate induced granulomas 
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Introduction 
Mycobacteria are responsible for a number of infectious pathologies that are a 
significant global health problem.  Disease caused by Mycobacterium tuberculosis 
(MTB) results in approximately 2 million deaths annually [1].  Infection usually presents 
as pulmonary pathology, characterized by the generation of granulomas that prevent 
bacterial dissemination.  However, extrapulmonary disease also occurs in which any 
organ can become infected including the bones, kidneys, central nervous system, and 
gastrointestinal tract [187].  The cytokine mechanisms that induce granuloma formation 
have not been fully elucidated.  Due to the increasing number of drugs developed to 
target cytokines in the therapy of immune-mediated disorders, it is essential to determine 
the role these mediators play in the formation and maintenance of mycobacterial induced 
granulomas. 
Tumor necrosis factor-α (TNF-α) is the major cytokine necessary for the 
generation and maintenance of MTB induced granulomas [188].  TNF-α has a number of 
immunologic functions that include activation of endothelial cells, initiation of 
apoptosis, and proliferation of thymocytes [189].  Antibody neutralization of TNF 
prevented control of infection with bacillus Calmette-Guérin (BCG) and granuloma 
formation in mice [190].  Mice deficient in the TNF receptor and wild-type mice 
administered a TNF-α neutralizing antibody rapidly succumb to infection with MTB 
[101].  Additionally, mice lacking TNF do not generate granulomas during 
mycobacterial infection, accompanied by delayed recruitment of CD11b+ cells and 
production of C-C and C-X-C chemokines [191].  TNF is also essential for long term 
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control of persistent infections, with elimination resulting in inability to maintain 
granulomas [192].  
Complement C5 is another potentially important mediator in the granulomatous 
response.  Its split product, C5a, recruits cells to sites of inflammation and promotes the 
synthesis of cytokine subsets, such as TNF-α, IL-6, and IL-12 [193].  A/J mice, which 
lack complement C5, have increased mortality accompanied by markedly increased 
inflammatory responses and do not form granulomas in a mouse model of MTB 
infection [97].  The complement deficient A/J mice had significantly earlier reactivation 
of latent infection, exacerbated responses in an induced chronic infection, and reduced 
macrophages synthesis of cytokines and chemokines in comparison to complement-
sufficient mice [98].  A study by Borders and colleagues [194] showed that mice 
deficient in the C5a receptor had exacerbated inflammatory responses with absence of 
granulomas.  Thus, complement C5 is likely involved in the early initiation of the 
granulomatous response, possibly due to recruitment of cells that produce regulating 
proinflammatory cytokines to the site of inflammation. 
Interleukin-6 (IL-6) is a proinflammatory mediator synthesized by fibroblasts, 
macrophages, B-cells, and T-cells that possibly plays a role in mycobacterial infections 
by its involvement in acute phase protein and immunoglobulin production, and adaptive 
cell activation [195].  In vitro studies possibly indicate a pathologic role for IL-6 in MTB 
infection, but these experiments need further clarification.  IL-6 synthesis by 
macrophages infected with mycobacteria decreases T-cell responses [106] in addition to 
decreasing transcriptional activation of interferon- γ (IFN- γ) in uninfected, nearby 
macrophages [196].  In vivo studies have generated mixed results.  One study found that 
 30 
MTB infection was lethal for mice lacking IL-6 [107]; however, another investigation 
using IL-6 -/- mice reported that the deficient mice were still able to control the infection 
despite delayed synthesis of IFN-γ [105].  Thus, IL-6 likely plays a role in the immune 
response to MTB, but its precise function is unclear.  
Trehalose-6,6’-dimycolate (TDM) is a glycolipid found on the mycobacterial cell 
wall.  Purified TDM causes lung pathology in mice that mimics some aspects of MTB 
infection, such as granuloma formation and induction of proinflammatory cytokines 
[197, 198].  TDM plays a number of important roles in the pathogenesis of MTB 
infection, including the induction of caseating granulomas [13, 110, 199].  The TDM 
model system may thus be a useful tool to explore the factors necessary for the early 
granulomatous response.  The precise roles for TNF-α, C5a, and IL-6 in initiation and 
maintenance of the granulomatous response to isolated TDM are unknown; thus, 
experiments were conducted to explore the responses of mice lacking these critical 
immune factors. 
 
Materials and Methods 
 Animals.  Three-to-five week-old, wild-type, female C57BL/6 mice and mice 
lacking TNF-α (B6;129S6-Tnftm1Gkl/J), C5a (B10.D2-Hc0H2dH2-T18c/oSnJ), or IL-6 
(B6.129S2-Il6tm1Kopf/J) were purchased from the Jackson Laboratories (Bar Harbor, 
ME).  Animal experiments were performed under the approval of the UTHSC animal 
ethics committee (AWP 04-065).  Four to six mice per group per indicated time points 
were used.  
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Preparation of bone marrow-derived macrophages, stimulation with TDM-coated 
microspheres, and MTB infection.  Bone marrow-derived macrophages from wild-type 
C57BL/6 and complement factor C5a deficient (A/J) mice were generated by previously 
described methods [200].  Briefly, femurs were flushed with McCoy’s media (Sigma, St. 
Louis, MO), and 2 x 106 cells were added to 24 well tissue culture plates (Corning 
Incorporated, Corning, NY).  Cells were cultured in McCoy’s media (Sigma) 
supplemented with 10% fetal bovine serum (FBS) (Sigma), 100 µg ml-1 gentamycin 
(Sigma), 100 U ml-1 penicillin (Sigma), and 10 ng ml-1 recombinant murine 
granulocyte/macrophage colony stimulating factor (GM-CSF; Chemicon, Billerica, 
MA).  The cells were cultured at 37 °C in 5% CO2 for seven days, with two media 
changes containing GM-CSF.  Finally, cells were washed and suspended in Dulbecco’s 
modified eagle’s medium (DMEM; Sigma) supplemented with 10% FBS.  
TDM-coated and BSA-coated microspheres were generated by previously 
described methods [112], and were a generous gift from C. Kan.  The microspheres were 
added to the bone marrow-derived macrophages at a ratio of 10 beads per cell.  IL-6 and 
TNF-α protein production was determined in the cell supernatants after a 72 hour 
incubation using an ELISA (see below).     
MTB Erdman (ATCC 35801) was grown to log phase in Dubos broth (Difco, 
Franklin Lakes, NJ) with 7.5% dextrose and 5% BSA as supplements.  Petroleum ether 
(Sigma) was use to extract mycobacterial surface lipids to generate delipidated MTB, as 
previously detailed [112, 114].  The bacteria were vortexed after adding petroleum ether 
for 2 minutes, after which they were incubated for 5 minutes at room temperature.  The 
bacteria were then centrifuged for 10 minutes at 500 g.  After removing the supernatants, 
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the extraction process was repeated two additional times followed by suspending the 
culture in phosphate buffered saline (PBS).  Lipid extraction by petroleum ether does not 
alter the acid fastness of organisms or viability [112, 114].  Delipidated MTB were 
reconstituted by adding 0.01% (50 µg ml-1) purified TDM (Sigma) in petroleum ether 
[112, 114].  The bacteria were resuspended in PBS after evaporation of the ether. 
Preparation of TDM, tissue processing, and histopathology.  A TDM oil-in-water 
emulsion was prepared by previously detailed methods [118], with minor modifications 
discussed below.  Mice were intravenously injected with 50 µL of emulsion, generated 
by dissolving 25 µg of purified TDM (Sigma) in 9:1 hexane/ethanol, after which the 
solvent was evaporated.  One µL of Drakeol (Penreco, Dickinson, TX) was 
homogenized into the TDM.  Finally, 48 µL of 0.2% Tween 80 (Mallinckrodt, 
Hazelwood, MO) in PBS was admixed.  Mice were sacrificed by cervical dislocation at 
days 0, 4, 7, and 14 after TDM challenge.  Lung tissue was aseptically removed, 
weighed, and prepared for analysis of cytokines or fixed in 10% formalin for histology.  
The lung weight index (LWI) was calculated as an indicator of inflammation intensity 
[129, 194, 201] using the following formula: 
 
Lung tissue (approximately 30 mg) was homogenized and put into 2 mL DMEM 
(Sigma) supplemented with 10% FBS, 0.01% L-Arginine (Sigma), 0.01% HEPES 
(Sigma), 50 µg/mL gentamycin (Sigma) and 100 µg/mL penicillin (Sigma).  Samples 
were cultured for 4 hours at 37 °C with 5% CO2.  The supernatants were kept at -20 °C 
until analysis by enzyme-linked immunoassay (ELISA).  For histopathologic studies, the 
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left lung was placed in 10% formalin, sectioned (5 µm thick), and stained with 
hematoxylin and eosin (H & E) per standard methodologies.  The remainder of the lung 
was frozen in RNA-Bee (TelTest, Inc., Friendswood, TX) and stored at -80 °C for RNA 
studies.  No significant differences were observed in histopathology or lung weight in 
mice given emulsion alone, as previously described [129].     
ELISA analysis for lung cytokine and chemokine protein.  Levels of interleukin-
1β (IL-1β), IL-6, interleukin-10 (IL-10), TNF-α, interleukin-12p40 (IL-12p40), IFN-γ, 
and macrophage inflammatory protein-1α (MIP-1α) in lung homogenates were analyzed 
by a sandwich ELISA as per the manufacturer’s instructions (R&D Systems, 
Minneapolis, MN).  Briefly, capture antibody was coated on to Costar 96-well plates 
followed by washing (0.5% Tween-20 in PBS) and blocking (1% BSA, 5% sucrose, 
0.05% NaN3 in PBS).  Lung homogenates were incubated at room temperature for 2 
hours, after which biotin-conjugated secondary antibodies were used for detection with 
visualization by streptavidin-horseradish peroxidase (R&D) and TMB Microwell 
Peroxidase Substrate (KPL, Gaithersburg, MD).  The reactions were stopped with 2 N 
H2SO4.  The absorbance was read at 570 nm and 450 nm using an ELISA plate reader 
(Molecular Devices, Menlo Park, CA).  The average of duplicate wells was generated 
using on a standard curve made for each assay with recombinant molecules supplied by 
the manufacturer (R&D).  The lower limit of detection was 15 - 32 pg/mL.   
Extraction of mRNA, reverse transcription, and real-time PCR.  Sectioned lung 
tissue was minced in 1 ml of RNA-Bee, and RNA extracted using previously detailed 
methods [120].  cDNA was generated from 2 µg RNA in First Strand buffer (250 mM 
Tris-HCL, pH 8.3, 375 mM KCl, 15 mM MgCl2) (Invitrogen, Carlsbad, CA), with 2.5 
 34 
mM deoxynucleotides-triphosphate (dNTPs) (Invitrogen), 0.1 M dithiothreitol (DTT) 
(Invitrogen), 20 U RNase inhibitor (Promega, Madison, WI), and 80 U random hexamer 
oligonucleotides (Roche Diagnostics GmbH, Mannheim, Germany).  200 U of 
SuperScript II reverse transcriptase (Invitrogen) was admixed after heating the reaction 
mixture to 70 °C for 5 minutes, followed by incubation at 42 °C for 50 minutes; the 
reactions were halted by heating to 70 °C for 15 minutes.  The samples were diluted 1:8 
with distilled water.             
cDNA was quantified with the Taqman assay using fluorogenic probes with 
FAM (6-carboxifluorescein) reporter and BHQ-1 (black hole quencher) quencher 
(Biosearch, Novato, CA).  The primer and probe sequences are shown in Table 2.1.  The 
reaction mixture contained 1X PCR Buffer (20 mM Tris-HCL pH 8.0, 100 mM KCl, 0.1 
mM EDTA, 1 mM DTT, 50% glycerol, 0.5% Tween 20, 0.5% Igepal CA-630) (5 Prime, 
Gaithersburg, MD), 200 nM dNTPs (Invitrogen), 1X ROX Reference Dye (Invitrogen), 
400 nM of each primer (Integrated DNA Technologies, Coralville, IA), 100 nM probe, 
and 1 U/45 µL Taq DNA Polymerase (5 Prime).  The ABI Prism 7700 Sequence 
Detection System (Applied Biosystems, Foster City, CA) was used for amplification.  
The reaction cycle consisted of 95 °C for one minute, followed by 40 cycles of a 12 
second step at 95 °C and a one minute step at 60 °C.  Data were analyzed by the -2ΔΔCT 
method using β-actin message as the calibrator [202]. 
Statistics.  The data are shown as the mean ± one standard deviation.  Two way 
ANOVA was used to determine differences between groups.  A p-value <0.05 was 
considered significant. 
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Table 2.1.  Oligonucleotide primers and probes. 
 
 
 
 
 
 
 
 
 
 
 
Protein Primers Probes
Sa 5' TCTGGCTCCTAGCACCATGA 5' ATCAAGATCATTGCTCCTCCTGAGCGC
AS 5' CCACCGATCCACACAGAGTACT
S 5' CTCATTGTGGCTGTGGAGAA 5' TGGCAGCTACCTGTGTCTTTCCCG
AS 5' GGTGCTCATGTCCTCATCCT
IL-6 S 5' CCCAATTTCCAATGCTCTC 5' TAGCCACTCCTTCTGTGACTCCAGCT 
AS 5' TGAATTGGATGGTCTTGGTC
S 5' CCGATGGGTTGTACCTTGTCT 5' TCTTCAAGGGACAAGGCTGCCCC
AS 5' TGGGTGAGGAGCACGTAGTC
S 5' ACTAAGAGAAACCGGCAGAT 5' TGCGCTGACTCCAAAGAGACC
AS 5' TTCAGTTCCAGGTCAGTGAT
S 5' AGCAACAGCAAGGCGAAA 5' TCAAACTTGGCAATACTCATGAATGCATCCT
AS 5' CTGGACCTGTGGGTTGTTGA
IL-12p40 S 5' AAGTGTGAAGCACCAAATTACTC 5' ACGGTTCACGTGCTCATGGCT
AS 5' TTCAAGTCCATGTTTCTTTGC
IL-4 S 5' ATCGGCATTTTGAACGAGGT 5' CAGGAGAAGGGACGCCATGCAC
AS 5' GACGTTTGGCACATCCATCT
IL-10 S 5' CAGCCGGGAAGACAATAACTG 5' CCCACTTCCCAGTCGGCCAG
AS 5' CCGCAGCTCTAGGAGCATG
S 5' CACTGGAGTTGTACGGCAGTG 5' TGAACCAAGGAGACGGAATACAGGGC
AS 5' AGAGCAGTGAGCGCTGAATC
IL-17 S 5' GCTCCAGAAGGCCCTCAGA 5' ACCTCAACCGTTCCACGTCAC
AS 5' CTTTCCCTCCGCATTGACA
aS, sense; AS, antisense
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Results 
TDM induced inflammatory response in wild-type and C5a deficient bone marrow 
derived macrophages. 
 TDM is a major generator of proinflammatory cytokines from monocytic cells 
[118].  The amounts of IL-6 and TNF-α were significantly increased in the supernatants 
from both wild-type C57BL/6 and C5a-deficient A/J bone marrow derived macrophages 
stimulated with TDM coated microspheres (Table 2.2).  Prior studies showed that 
removal of surface TDM from MTB resulted in a significantly diminished 
proinflammatory response [200].  A number of recent studies suggest that complement 
factors play an important role in this response [97, 194]; thus, IL-6 and TNF-α were also 
evaluated in bone marrow derived macrophages lacking complement C5a and infected 
with MTB, or organisms from which surface TDM (delipidated; dMtb) was removed. 
C5a-sufficient derived cells were used as a comparison.  Delipidation of both groups 
resulted in a significantly decreased cytokine response.   Of importance, the C5a-
deficient derived cell response was always significantly decreased compared to C5a-
sufficient derived cells.  The cytokine responses were almost completely restored when 
the cells were stimulated with organisms that had been reconstituted with purified TDM 
(r-dMtb), suggesting the importance of TDM in generating proinflammatory responses to 
MTB.  
 
Dysregulated TDM-induced responses in TNF-α, C5a, and IL-6 knock-out mice.   
 Lung weight indices (LWI) were determined as an indicator of general 
inflammation for wild-type and deficient mice after intravenous challenge with TDM  
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TNF-α 
BSA 
beads TDM beads MTB dMtb r-dMtb uninfected 
C5a-sufficient 24 (2) 1294 (173)* 541 (70) 253 (39)** 461 (44) 19 (5) 
C5a-deficient 14 (1) 322 (19)* 303 (50) 166 (32)** 339 (50) 10 (1) 
       
IL-6       
C5a-sufficient 7 (1) 245 (4)* 335 (75) 102 (6)** 227 (14) 5 (1) 
C5a-deficient < 10 24 (4) 30 (1) < 10 < 10 < 10 
 
 
Table 2.2. TDM induced cytokine production in C5a-sufficient and C5a-deficient 
bone marrow derived macrophages. Production of TNF-α and IL-6 by bone marrow 
derived macrophages to TDM-coated beads, native MTB, delipidated Mtb (dMtb), 
delipidated Mtb reconstituted with TDM (r-dMtb), or untreated cells. Values were 
measured by ELISA and expressed as average pg protein/106 macrophages (±SD), three 
replicates per time point. *p<0.05 between treatment groups (TDM-coated vs. uncoated) 
as analyzed by Student’s t test; **p<0.05 between groups compared against dMtb or 
against TDM reconstituted organisms; all responses from C5a-deficient (A/J) derived 
BMMs were significantly lower (p<0.05) than the C5a-sufficient (C57BL/6) BMM 
treated in the identical manner.  
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(Table 2.3).  The wild-type, C5a -/-, and IL-6 had significantly (p<0.05) increased LWI 
at both 4 and 7 days post-TDM challenge compared to untreated controls, or in 
comparison to emulsion controls (data not shown, [97]).  In comparison, the LWI of the 
TNF-α -/- mice were unchanged after TDM-challenge, indicating that the TNF-α 
deficient mice did not generate a significant inflammatory reaction to TDM. 
 
Histopathology is altered in TNF-α, C5a, and IL-6 deficient mice in response to TDM.   
C57BL/6 mice form cohesive granulomas after intravenous challenge with TDM 
(Figure 2.1).  Small, focal, monocytic clusters of cells were observed 4 days post-TDM 
challenge.  The granulomas increased in both size and number by day 7.  The 
granulomas were found in the lung parenchyma, without occlusion of lymphatics or 
blood vessels.  The granulomatous response completely resolved by day 14.   
 The TNF-α -/- mice did not produce a histopathological response to TDM, in 
contrast to the wild-type mice.  Inflammation was not observed by day 4 after TDM 
challenge.  On day 7, examination revealed a few cellular infiltrates that did not form 
obvious granulomas; infiltrating cells were primarily monocytic.  Occlusion of 
vasculature, edema, and pneumonitis were not observed. 
 C5a deficient mice also did not generate granulomas to isolated TDM.  However, 
the histopathology was markedly different from the TNF-α -/- mice.  The complement 
knock-out mice had a marked inflammatory response that was non-focal at day 4.  They 
did not form cohesive cellular aggregates at day 7, and had a considerable amount of 
monocytic and lymphocytic infiltrates.  The lung parenchyma demonstrated occluded  
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  Day 0  Day 4  Day 7  Day 14 
wild-type  1.00 ± 0.033  1.31 ± 0.073  1.63 ± 0.232  1.06 ± 0.154 
TNF-α -/-  0.98 ± 0.026  0.99 ± 0.012*  1.01 ± 0.010*  0.96 ± 0.035 
C5a -/-  0.93 ± 0.144  1.32 ± 0.156  1.53 ± 0.157  1.04 ± 0.196 
IL-6 -/-  1.02 ± 0.048  1.30 ± 0.051  1.55 ± 0.082  1.19 ± 0.216 
 
Table 2.3. Lung Weight Indices Following TDM Administration.  Lung weight 
indices were calculated at days 0, 4, 7, and 14 post-TDM administration.  Individual 
values are average responses (±SD) and compared to wild-type C57BL/6 mice (* 
p<0.05) at each indicated time point.  
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Figure 2.1. Granulomatous response to TDM in mice deficient in TNF-α, C5a, 
or IL-6. Wild-type mice challenged with mycobacterial TDM demonstrate small 
focal pulmonary granulomas by 4 days post-TDM administration, which peak at 
day 7 and resolve by day 14. In comparison, challenge of TNF-α-deficient mice 
did not elicit significant histopathology, with failure to mount significant 
inflammation in the lung. Mice with deficiency in C5a demonstrated a non-focal 
inflammatory response by day 4, and with no cellular aggregation of 
accompanying lymphocytic and monocytic infiltration or true resolution by 14 
days post-challenge. The IL-6-deficient mice initiated granuloma histopathology, 
but by day 7 exhibited marked monocytic infiltration, lymphocytic cuffing around 
occluded vesicles, and edema with accompanied alveolar cell wall thickening. 
Sections representative of 4–6 mice per group. Hematoxylin and eosin staining; 
magnification ×40. 
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vessels and areas of pulmonary edema.  Incomplete resolution of the response occurred, 
with some degree of inflammation evident on day 14. 
 The IL-6 -/- mice appeared to initially generate granulomas after TDM challenge, 
with monocytic, focal clusters visible at day 4.  However, these mice did not maintain 
this response.  Acute inflammation was increased with considerable monocytic 
infiltration apparent at day 7.  Lymphocytic cuffing of occluded blood vessels was 
observed, along with alveolar cell wall thickening and edema.  This response appeared to 
be transient, with resolution occurring by day 14. 
 
Dysregulated cytokine and chemokine protein and mRNA expression in deficient mice 
following TDM challenge 
Production of cytokine and chemokine proteins were evaluated in the lungs of 
mice administered TDM (Figures 2.2 and 2.3).  Wild-type mice produced significantly 
higher (p<0.05) IL-6, TNF-α, IL-1β, IL-12p40, IL-10, and MIP-1α on both days 4 and 7 
in compared to naive mice.  Additionally, there was a transient, significant, increase in 
IFN-γ synthesis on day 4.  Cytokine protein levels returned to near normal levels by day 
14 after TDM administration.  
Lung cytokine protein production in control and deficient mice was markedly 
different 4 days post TDM challenge.  The TNF-α knock-out mice failed to elevate 
levels of cytokines and chemokines after TDM challenge.  The amount of IL-6, IL-1β, 
IFN-γ, IL-12p40, IL-10, and MIP-1α were not different compared to naive mice, and 
were significantly below values generated by wild-type mice at all time points.  TNF-α 
was not produced by the TNF-α -/- mice (data not shown). 
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Figure 2.2. TDM-elicited proinflammatory mediator production from lungs of 
deficient and wild-type mice.  Levels of pulmonary proinflammatory mediators 
IL-1β, IL-6 and TNF-α were quantified post-challenge in the lungs of mice 
administered TDM. Mean values per lung are shown for mice deficient in TNF-α, 
C5a or IL-6 prior to challenge (day 0) and at 4, 7 and 14 days post-TDM 
challenge. Comparisons are made to the wild-type control animals administered 
TDM. Data are represented as the mean ± SD for duplicate wells per mouse (n = 
4–6 mice per group per time point). *P < 0.05; nd, none detected. 
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Figure 2.3. TDM-elicited cytokine production from lungs of deficient and 
wild-type mice. Levels of pulmonary cytokines IL-12p40, IL-10, MIP-1α and 
IFN-1γ were quantified post-challenge in the lungs of mice administered TDM. 
Mean values per lung are shown for mice deficient in TNF-α, C5a or IL-6 prior to 
challenge (day 0) and at 4, 7 and 14 days post-TDM challenge. Comparisons are 
made to the wild-type control animals administered TDM. Data are represented 
as the mean ± SD for duplicate wells per mouse (n = 4–6 mice per group per time 
point). *P < 0.05. 
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The complement C5a knock-out strain had significantly decreased lung synthesis 
of IL-1β, IL-6, TNF-α, IFN-γ, and MIP-1α on day 4, in comparison to the wild-type 
mice.  However, levels of protein became comparable to wild-type mice by day 7.  MIP-
1α, a chemokine that directs migration of a variety of effector cells, was significantly 
decreased in the C5a deficient mice at day 4.  Additionally, IL-12p40 was also 
significantly reduced on all time points compared to complement-sufficient mice. 
The IL-6 -/- mice also had decreased synthesis of IL-1β, TNF-α, IL-12p40 and 
IFN-γ in the lungs 4 days after TDM administration. The levels of these cytokines were 
similar to the wild-type mice by day 7.  IL-10 levels were significantly reduced at day 7 
in the IL-6 knock-out mice.  MIP-1α levels were not significantly different from the 
wild-type mice on any time points tested.  Production of IL-6 protein in the IL-6 
deficient mice was below the limit of detection (data not shown). 
 Examination of mRNA in wild-type and deficient mice given TDM generated 
similar results to lung protein levels (Table 2.4).  The wild-type C57BL/6 mice produced 
a significant increase (20-fold or greater) in proinflammatory message of IL-1β, IL-6, 
TNF-α, and MIP-1α, in comparison to naive or emulsion treated controls (not shown).  A 
modest increase in IL-12p40 was noted on both days 4 and 7.  There was additionally an 
early rise in expression of IL-10 and IFN-γ that decreased on day 7.  The deficient mice 
had reduced expression of all cytokines examined, with the exception of IL-12p40, in 
comparison to wild-type mice.  Significant differences in message levels in the knockout 
strains compared to wild-type control mice (p<0.05) are shown in Table 2.4.  Expression 
of IL-6 or TNF-α in the IL-6 -/- mice or the TNF-α -/- mice, respectively, was not 
observed. 
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Table 3. Relative Change in mRNA Following TDM administration 
a
 
 
 
IL-1â IL-6 TNF-á MIP-1á IFN-ã IL-12p40 IL-10 
Day 4        
     wild-type 23.89 ± 9.37 32.01 ± 7.71 20.71 ± 3.67 29.57 ± 10.59 23.09 ± 14.60 2.99 ± 0.32 29.17 ± 17.71 
      TNF-á -/- 3.79 ± 2.24* 5.45 ± 3.41* --- 4.61 ± 1.87* 4.12 ± 1.76* 3.21 ± 1.74 7.10 ± 4.02* 
      C5a -/- 15.25 ± 1.94* 16.57 ± 6.76 31.34 ± 13.99 19.59 ± 20.04 12.43 ± 2.10* 1.35 ± 0.98 11.45 ± 7.86* 
      IL-6 -/- 5.02 ± 1.42* --- 5.72 ± 1.50* 5.54 ± 2.00* 7.02 ± 2.48* 2.04 ± 1.02 7.02 ± 3.22* 
        
Day 7        
      wild-type 32.96 ± 10.66 27.87 ± 26.62 43.59 ± 13.60 42.51 ± 16.84 9.63 ± 5.95 2.19 ± 0.72 11.84 ± 3.34 
      TNF-á -/- 2.54 ± 1.73* 1.08 ± 0.88* --- 2.32 ± 1.77* 2.31 ± 1.36 0.89 ± 0.68 2.49 ± 1.64 
      C5a -/-  15.94 ± 4.17* 3.28 ± 0.97 * 18.44 ± 10.55* 16.36 ± 10.88* 10.57 ± 5.37 1.79 ± 0.45 5.73 ± 1.20 
      IL-6 -/- 5.04 ± 1.77* --- 5.97 ± 2.21* 7.04 ± 1.89* 2.18 ± 0.87 0.95 ± 0.55 2.07 ± 0.81 
        
Day 14        
      wild-type 0.61 ± 0.20 0.53 ± 0.05 10.29 ± 15.73 0.72 ± 0.56 1.75 ± 1.04 1.09 ± 0.29 0.67 ± 0.30 
      TNF-á -/- 2.30 ± 1.25 1.50 ± 1.53 --- 2.14 ± 1.14 3.42 ± 1.97 1.13 ± 0.69 2.16 ± 1.39 
      C5a -/- 0.68 ± 0.55 0.44 ± 0.22 0.63 ± 0.60 0.94 ± 0.55 1.37 ± 1.48 1.58 ± 1.19 1.79 ± 2.24 
      IL-6 -/- 2.01 ± 1.32 --- 3.29 ± 2.72 2.65 ± 1.05 2.56 ± 1.71 1.35 ± 0.60 3.41 ± 2.29  
Table 2.4. Relative Change in mRNA following TDM administration. 
Proinflammatory mediator mRNAs in lungs of mice deficient in TNF-α, C5a, or IL-6 
were evaluated by RT-PCR and compared to wild-type controls, after challenge with 
TDM.  Results shown are normalized to β-actin, and represented as fold-change from 
non-injected mice.  Data are expressed as mean values with standard deviations.  * 
p<0.05.  
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Discussion 
 Approximately one-third of the world’s population is considered latently infected 
with MTB [203].  Granuloma formation is an essential host response for containment of 
the bacilli and requires concerted regulation of immunological mediators.  An increasing 
number of chemotherapeutics that target cytokines for the treatment of immune-
mediated diseases makes it essential to explore how cytokines are involved in the 
initiation and maintenance of MTB-induced granulomas.  For example, use of the TNF-α 
neutralizing antibody infliximab resulted in modulated inflammatory patterns that caused 
reactivation of latent pulmonary TB and greater occurrences of extrapulmonary disease 
[204].  Furthermore, cytokines are being considered as adjunct therapeutics to enhance 
antibiotic efficacy for TB treatment in cases of multidrug-resistant strains and 
immunodeficient patients [205, 206].  An understanding the implications of cytokine 
dysregulation on granulomatous responses is essential when evaluating treatment for 
these individuals. 
 TNF-α is a central mediator in initiation of granuloma formation.  TNF-α 
deficient mice did not generate granulomas following challenge with MTB, instead 
forming necrotic lesions lacking epithelioid cells [207].  The TNF-α deficient mice in the 
results reported in this study did not generate a histological response following challenge 
with TDM, accompanied by markedly reduced cytokine protein and message synthesis.  
Of importance, these deficient mice also had decreased amounts of the Th1 cytokines 
IL-12p40 and INF-γ.  A study by Kindler and colleagues [190] noted that antibody 
neutralization of TNF inhibited granuloma formation following infection with BCG and 
dissolved chronic granulomas.  Transgenic mice producing high levels of human soluble 
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TNF receptor 1 also did not form granulomas to BCG, accompanied by delayed 
synthesis of both IL-12p40 and IFN-γ [208].  The absence of granuloma generation in 
TNF-α -/- mice is possibly a result of an inability to synthesize a cytokine cascade that 
includes chemokines that recruit both monocytes and T-cells to lung tissue.  TNF 
neutralization in macrophage cultures infected with MTB resulted in a decrease in 
synthesis of CCL5, CXCL9, and CXCL10 [209].  The same investigation reported that 
CD11b+ cells recovered from mice deficient in the 55 kDa TNF receptor and infected 
with MTB had delayed synthesis of chemokines.  Additionally, TNF-α is an essential 
regulator of Th1 immune responses necessary for control of mycobacterial infections.  
Treatment of macrophages with a TNF-neutralizing antibody or macrophages deficient 
in the TNF receptor 1 did not synthesize IL-12 following BCG infection [210].  TNF-α 
was necessary for the initiation of IL-12-induced Th1 responses in BALB/c mice [211].  
Furthermore, Ahlers et al. [212] reported that a synergism between TNF-α and IL-12 
was essential to promote the IL-12Rβ2 chain and IFN-γ to induce the development of 
Th1 cells.  The essential role of T cells in TDM-induced granulomas has been explored 
[120, 213], with T helper cells of central importance for the generation of hypersensitive 
pathology [120, 214]. 
 The studies reported here suggest that complement C5a is necessary for 
development of cohesive granulomas following challenge with mycobacterial glycolipid 
TDM, once the response is initiated.  C5a deficiency resulted in development of 
pneumonitis pathology accompanied by edema and monocytic infiltration with 
incomplete resolution of inflammatory responses, suggesting a role for C5a in 
granuloma maintenance and resolution.  Furthermore, the complement knock-out mice 
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had reduced early synthesis of proinflammatory cytokines accompanied by consistently 
decreased production of IL-12p40.  A/J mice, which are deficient in the fifth component 
of complement along with other defects, failed to generate granulomas and had increased 
mortality to MTB infection [98].  A study using the same C5a deficient mice used in this 
investigation reported increased MTB growth in lung tissue in addition to failing to form 
granulomas [97].  Both investigations reported early decreases in cytokines and 
chemokines, similar to results presented here for the chemokine MIP-1α.  Complement 
C5 is necessary for variety of additional processes that are possibly involved in 
granuloma formation or maintenance.  C5a promotes NFκB, a regulator of expression of 
a number of inflammatory mediators, including TNF-α and IL-6 [215].  Both C5a and 
C5b induce adhesion molecule expression on neutrophils, endothelial cells, and 
macrophages [216, 217].  Finally, C5 is necessary for IL-12 generated cell-mediated 
immunity [218].  
 The investigations presented here additionally suggest that IL-6 plays a role in 
maintenance of established granulomas, but not in their initiation.  The IL-6 -/- mice 
generated similar granulomas to wild-type mice after TDM challenge at day 4.  Of 
significance, this occurred in the presence of decreased levels of proinflammatory 
cytokines.  However, the granulomatous response was not maintained through day 7, 
despite levels of cytokines similar to those of wild-type mice.  The IL-6 deficient mice 
had severe, edematous pathology; a recent investigation demonstrated that IL-6 is 
necessary for regulating local concentrations of glucocorticoids that modulate 
pathological responses [219].  Investigations on the role of IL-6 in control of 
mycobacterial infections have yielded conflicting results.  Even less is known of the role 
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IL-6 plays in granuloma formation during MTB infection.  Ladel and coworkers [107] 
reported that IL-6 deficient mice had significantly higher bacterial loads and ultimately 
succumbed to infection, while Saunders and colleagues [105] demonstrated that mice 
lacking IL-6 were able to contain the infection in the presence of higher bacterial 
burdens and decreased early IFN-γ production.  The conflicting results between these 
two studies may be due to the number of organisms and routes used for the infectious 
challenge.  Further complicating interpretation, M. avium-infected mice treated with IL-6 
neutralizing antibodies had increased bacterial loads; however, no differences in 
granuloma size or number were observed [220].  Infection of IL-6 knock-out mice with 
M. avium resulted in fewer necrotic lesions in comparison to wild-type mice [221].  IL-6 
-/-  mice infected with Rhodococcus aurantiacus,  an organism that produces short chain 
TDM and induces Th1 granulomas that are similar to those induced by mycobacterial 
organisms, reported increased inflammatory infiltrates after challenge and granulomas 
that were increased in size and had central necrosis in comparison to the wild-type mice 
[222].  IL-6 is generally thought of as a Th2 cytokine [195, 223].  However, this may not 
be a stand-fast rule in all models of intracellular infections [224].  IL-6 has been reported 
to play a role in the development of T-cell responses against M. avium [220].  It is well-
established that maintenance of the granulomatous response requires antigen-specific T-
cells [225].  Thus, IL-6 is possibly a regulator of T-cell responses that are essential for 
maintenance of established granulomas, especially when persistent antigen is present.  
 The TDM model of granuloma formation mimics in part certain aspects of 
mycobacterial histopathology seen during aerosol challenges of mice.  Thus, this model 
may be useful for investigations of the roles of complement and certain cytokine 
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mediators involved in the early response to mycobacterial glycolipid antigens.  The 
investigations reported here suggest that TNF-α is an essential mediator required in 
initiation of TDM-induced granulomas (Figure 2.4).  Once the granulomas have been 
initiated, mediators such as complement component C5a and IL-6 generate secondary 
responses.  C5a is most likely is an important regulator of responses that generate 
cohesive granuloma pathology, while IL-6 is involved in the maintenance of established 
granulomas.  Deficiency of any of these mediators results in an inability to effectively 
generate and maintain a granulomatous response, and would thus also likely be 
important in the control of mycobacterial infections. 
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Figure 2.4. Proposed mechanism for TDM-induced granulomas.  TNF-α is 
essential for a histological response to TDM. Once a response has been initiated, 
complement C5a and IL-6 recruit cells that produce regulating cytokines and 
upregulate integrin that allow cells to form organized, cohesive structures.  
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Chapter Three 
Lactoferrin decreases mycobacterial antigen induced lung immunopathology 
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The studies presented in this chapter were published in the journal Translational 
Research, 2010 156: 207 – 15 [226] 
 
Introduction 
Tuberculosis (TB) causes approximately 1.8 million deaths annually, making it 
the leading cause of death worldwide due to bacterial infections [203].  Additionally, 
roughly one-third of the world’s population is considered latently infected with 
Mycobacterium tuberculosis (MTB) [203].  Effective chemotherapy for TB is available; 
however, treatment requires at least six months of a complex multi-drug regimen for 
which effectiveness is threatened due to the emergence of multi-drug resistant 
organisms.  Unfortunately, there have been no new commercial antibiotics against TB 
created since rifampin was invented in the 1960s [3].  Therefore, new agents with 
activity against MTB or a favorable effect when used in combination with the standard 
anti-TB drugs are desperately needed. 
The normal, immune competent host responds to infection with MTB by forming 
granulomas, which structurally consist of central infected macrophages that can 
differentiate into foamy macrophages, epithelioid cells, and Langhan’s giant cells [17].  
A layer of fibrosis develops and surrounds the infected macrophages, which prevents 
bacterial dissemination.  However, granulomas also result in physical separation of 
infected cells from effector lymphocytes that are capable of eliminating infected cells 
[17].  Additionally, the TB bacilli enter a state of non-replicating persistence within 
granulomas; these organisms are resistant to sterilizing antimicrobials [131, 132].  Most 
granulomas heal, but viable MTB persist.  Individuals at this stage of infection are 
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known as latently infected because they do not have clinical symptoms of disease, 
sputums do not contain acid-fast bacilli, and chest X-rays are stable [227].  However, a 
small percentage of patients experience reactivation of latent disease that histologically 
is characterized as a lipid pneumonia that may undergo necrosis to generate cavitary 
lesions [11].  The resulting lung damage causes a productive cough that generates 
infectious aerosols, which may infect a new individual.  Therefore, modulation of TB-
induced inflammatory pathology will likely decrease morbidity, facilitate improved 
response to antibiotics, and limit disease transmission. 
Increasing evidence identifies lactoferrin as a modulator of the immune response 
to a number of inflammatory and injurious agents.  Lactoferrin is a component of the 
transferrin family of glycoproteins and is produced in neutrophil granules and mucosal 
secretions [140].  Lactoferrin receptors are found on numerous cells of the immune 
system, such as macrophages, dendritic cells, and T-cells [144-146].  Lactoferrin effects 
include macrophage activation, enhancement of polymorphonuclear cell phagocytosis, 
increasing killer cell activity, and maturation of B- and T-cells [148, 149, 228-230].  Of 
significance, lactoferrin alters macrophage cytokine production depending on the 
environmental context [142, 156, 231].  For example, addition of lactoferrin to 
macrophages stimulated with low levels of LPS produced increased levels of 
proinflammatory cytokines [175].  However, macrophages fully stimulated with LPS 
and given lactoferrin had decreased cytokine production.  Of importance to the studies 
proposed here, lactoferrin protects against immune-mediated tissue damage in a number 
of model systems.  Mice injected with LPS and treated with lactoferrin had decreased 
gut tissue destruction and increased survival [140, 183].  Additionally, lactoferrin as an 
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adjuvant to the BCG vaccine resulted in decreased lung damage and increased protection 
following an aerosol TB challenge [232]. 
Trehalose-6’6-dimycolate (TDM) is the most abundant glycolipid produced by 
MTB.  TDM has multiple hypothesized roles in MTB pathogenesis [13], including 
involvement in the formation of lung caseation [110].  TDM prepared in emulsion form 
and injected into mice intravenously induces lung pathology that mimics certain aspects 
of MTB infection, such as production of proinflammatory cytokines and granuloma 
formation.  The TDM granuloma model has been used to explore the immunological 
mediators involved in initiation of the granulomatous response [119, 130].  TDM 
induces foreign body granulomas in naïve mice [118, 233], and hypersensitive 
granulomas in previously sensitized mice [69, 110, 121, 213]. Thus, this model system 
may be used to explore the potential of immunomodulators to modulate granuloma 
structure. 
 
Materials and Methods 
Animals.  Four-week old, female C57BL/6 mice were purchased from the 
Jackson Laboratories (Bar Harbor, ME).  Animal studies were conducted under approval 
by the UTHSC Institutional Review Board (protocol number HSC-AWP 07-093).  Eight 
mice were used per group, for the time points indicated. 
Lactoferrin and MTB.  Bovine-derived lactoferrin (>95% purity, <20% iron 
saturated, <0.2 endotoxin units/mg) was purchased from PharmaReview Corporation 
(Houston, TX).  Lactoferrin was dissolved in phosphate buffered saline (PBS), and 
stored at -80°C until use.  
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MTB Erdman (American Type Cell Culture 35801) was grown in 7H9 broth 
(Remel, Lenesa, KS) with 10% supplement at 37°C to logarithmic phase.  The MTB 
were diluted in 1X PBS using McFarland standards (Sigma, St. Louis, MO) to 3 x 108 
bacteria per ml.  The final bacterial concentration was confirmed by plating serial 
dilutions onto 7H11 plates (Remel), and counted after incubating at 37°C for 3-4 weeks.   
Generation of bone marrow-derived macrophages (BMM), stimulation with 
TDM-coated beads, and MTB infection.  BMMs from C57BL/6 mice were generated by 
previously detailed procedures [155].  McCoy’s medium (Sigma) was used to flush 
femurs, followed by adding 5 x 105 of the recovered cells to 24-well tissue culture plates 
(Corning, Corning, NY).  The cells were cultured in McCoy’s medium supplemented 
with 10% fetal bovine serum (FBS) (Sigma), antibiotics (100 µg/ml penicillin G and 50 
µg/ml gentamycin) (Sigma), and 10 ng/ml recombinant murine granulocyte/macrophage 
colony stimulating factor (GM-CSF) (Cell Sciences, Canton, MA).  Cells were cultured 
at 37°C with 5% CO2 for one week, with two additional media changes containing GM-
CSF.  The cells were washed one time with 1X PBS and the media changed to 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS, 0.01% HEPES (Sigma), 
and 0.01% L-arginine (Sigma).  The cells were rested overnight and then stimulated with 
TDM-coated microspheres or infected with MTB. 
TDM- and BSA-coated beads were generated as per previously described 
methods [23], and were a generous gift from C. Kan.  The beads were briefly sonicated 
and then added to the BMMs at a ratio of 10 beads per one cell with or without 100 
µg/ml lactoferrin that was added simultaneously with bead stimulation or three hours 
later.  Alternatively, the BMM were infected with MTB using a multiplicity of infection 
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(MOI) of 1:1 in the presence or absence of lactoferrin (100 µg/ml) added at the same 
time as infection or three hours after.  For both bead stimulation and infection, the 
supernatants were collected after 24 and 72 hours of incubation and analyzed for 
cytokine protein production by ELISA (see below). 
In vivo challenge with TDM, tissue processing, and lung immunopathology.  An 
oil-in-water emulsion of TDM was generated by previously described methods [118, 
119].  Briefly, mice were intravenously injected in the tail vein with 50 µl of the 
emulsion.  The TDM emulsion was generated by dissolving 25 µg of purified TDM 
(Sigma) in 9:1 hexane/ethanol, after which the solvent was evaporated.  Two percent 
Drakeol (Penreco, Dickinson, TX) was homogenized into the TDM.  Finally, 0.2% 
Tween 80 (Mallinckrodt, Hazelwood, MO) in PBS was admixed.  A control emulsion 
lacking TDM was also generated.  Subsets of mice were given either 1 mg of lactoferrin 
or 1 mg of bovine apo-transferrin (Sigma) in 100 µl of PBS that was administered 
intravenously 24 hours after TDM challenge.   
Mice were sacrificed at 0, 4, and 7 days after challenge with TDM.  The lungs 
were immediately removed, weighed, and sectioned for cytokine analysis or histological 
studies.  Approximately 30 mg of lung tissue was minced and put into 2 ml of DMEM 
and cultured at 37 °C for 4 hours.  The supernatants were collected and stored at -20 °C 
until ELISA analysis for cytokine protein production.  For histological studies, the left 
lung was fixed in 10% buffered formalin, sectioned (5 µm), and stained with 
hematoxylin and eosin per standard methods.  The entire 5 µm lung section for at least 6 
mice per group was photographed with a 2x objective. A quantitative analysis was 
performed with the NIH Image J program (U.S. National Institutes of Health, available 
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at http://rsb.info.nih.gov/nih-image/).  The total number of granulomas was counted over 
an entire section of the lung.  The average granuloma size was calculated using a random 
selection of 10 granulomas in 3 different microscopic fields for each mouse.    
The lung production of IL-1β, IL-6, TNF-α, IL-12p40, IL-10, IFN-γ, and TGF-β 
was determined using a sandwich ELISA according to the manufacturer’s instructions 
(R&D Systems, Minneapolis, MN).  The average of duplicate wells was determined by a 
standard curve created for each assay by use of manufacturer supplied recombinant 
molecules.  The limit of detection sensitivity was 15-32 pg/ml, according to the 
manufacturer.   
Statistics.  The data are shown as the mean ± 1 SD.  Two-way ANOVA was used 
to evaluate the differences between groups using GraphPad Prism software (GraphPad 
Software, La Jolla, CA).  Statistical significance was defined as a p-value of < 0.05.          
 
Results 
Lactoferrin modulates bone marrow-derived macrophage inflammatory response to 
isolated TDM. 
 TDM induces proinflammatory cytokine production by macrophages [17, 118, 
200].  TNF-α, IL-6, and IL-12p40 production were significantly increased in BMMs 
stimulated with TDM-coated microspheres, in comparison to macrophages given BSA-
coated beads (Figure 3.1).  In contrast, TGF-β production significantly decreased with 
TDM-bead challenge.  Treating the BMM with 100 µg/ml bovine lactoferrin 
simultaneously with TDM bead stimulation or three hours later resulted in markedly 
decreased synthesis of TNF-α, IL-6, and IL-12p40 that was accompanied by increased  
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Figure 3.1. Lactoferrin modulation of TNF-α, IL-6, IL-12p40, and TGF-β 
production by BMM in response to TDM-coated beads.  Cells were treated 
with 3 µm BSA- or TDM-coated beads alone at a ratio 0f 10:1, 100 µg/ml 
lactoferrin at the same time as beads stimulation, or 100 µg/ml lactoferrin 3 
hours after bead addition.  Values were measured by ELISA and expressed as 
mean pg/ml with SD.  * p<0.05 compared to treatment with TDM-coated beads 
alone. 
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production of TGF-β. TGF-β was elevated when the cells were stimulated with control 
BSA-coated beads and given lactoferrin, as has been previously described [157].  
 
Lactoferrin decreases TDM-induced immunopathology. 
 C57BL/6 mice challenged with TDM generated lung granulomas following a 
single intravenous dose.  Focal, small, monocytic clusters were visible by 4 days after 
challenge with TDM (Figure 3.2A).  Granuloma size and number increased by day 7 
(Figure 3.2B) and was accompanied by other pathological manifestations, such as 
perivascular cuffing of lymphocytes.  Mice given an emulsion control without TDM did 
not generate granulomas and had normal lung histology.  Mice administered TDM and 
treated with 1 mg of intravenous bovine lactoferrin 24 hours after challenge had smaller 
and fewer granulomas, with the granulomatous response significantly decreased at 7 
days.  This response is not likely attributed to lactoferrin’s iron binding capacity because 
mice given transferrin, an iron-binding control, did not have altered granuloma size or 
number.   
 
Lung cytokine protein levels in mice challenged with TDM and treated with lactoferrin. 
 The levels of lung cytokines were examined in mice administered TDM (Figures 
3.3 and 3.4).  Mice challenged with the TDM emulsion had significantly increased levels 
of IL-1β, IL-6, TNF-α, IL-12p40, and IFN-γ at 4 and 7 days post-challenge in 
comparison to mice given an emulsion control without TDM (Figure 3.3).  Mice given 1 
mg of bovine lactoferrin intravenously 24 hours post-TDM administration produced  
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Day 4 Day 7 
Emulsion 
control 
TDM 
emulsion 
TDM plus  
lactoferrin 
Figure 3.2. Granulomatous response to TDM in lactoferrin treated mice. A) 
Mice were challenged with 25 µg TDM prepared in a water-in-oil emulsion.  One 
mg of lactoferrin or transferrin (not shown) was administered 24 hours post-TDM 
challenge.  Hematoxylin and eosin staining, magnification 100X.  B) Number of 
lung granulomas per mm2 and the size of the granulomas (µm2).  Granulomas were 
enumerated  and measured as described in the materials and methods section.  Data 
are expressed as the mean ± SD.  * p<0.05 with comparisons made to the mice 
administered the TDM emulsion.   
A. 
B. 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Figure 3.3. Production of pro-inflammatory mediators in mice challenged with 
TDM alone or with lactoferrin.  The levels of TNF-α, IL-1β, IL-6, IL-12p40, and 
IFN-γ in lung tissue were determined by ELISA.  Data are shown as the mean with 
standard deviation.  N = 8 mice per group, per time point.  *p<0.05 with 
comparison to the TDM emulsion treated mice.  
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Figure 3.4.  Lactoferrin induced production of anti-inflammatory 
cytokines in TDM challenged mice.  The levels of IL-10 and TGF-β were 
quantified in lung tissue homogenates by ELISA.  Data are expressed as the 
mean with standard deviation.  N = 8 mice per group, per time points 
indicated.  *p<0.05, comparisons made to the TDM-treated mice.  
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similar levels of most pro-inflammatory cytokines, except for decreased IL-1β at day 7.  
Of potential significance, the levels of TNF-α and IFN-γ were not significantly altered in 
the mice treated with lactoferrin.  In comparison, the amounts of IL-10 and TGF-β, 
cytokines that can have anti-inflammatory functions, were elevated at day 4 and day 7, 
respectively, in the mice treated with lactoferrin (Figure 3.4).  Mice given transferrin 24 
hours after the mice were challenged with TDM produced similar levels of cytokines in 
comparison to the mice administered a TDM emulsion alone. 
 
Lactoferrin modulation of BMM cytokine production in response to mycobacterial 
infection 
Certain proinflammatory cytokines such as TNF-α are of critical importance for 
host defense during MTB infection [190, 207, 234].  Thus, there was concern that the 
decrease in TNF-α production from BMMs stimulated with TDM-coated beads and 
treated with lactoferrin may produce favorable conditions for MTB proliferation within 
host cells.  Thus, C57BL/6 BMMs were infected with MTB in the presence or absence 
of lactoferrin.  Production of cytokines in response to MTB infection is presented in 
Figure 3.5.  TNF-α levels were significantly increased in BMMs treated with lactoferrin 
either simultaneously with bacterial seeding or three hours after.  IL-6 was significantly 
decreased, and IL-12p40 production was not altered.  Additionally, TGF-β was 
significantly elevated at 72 hours post-infection.  These data suggest a potential for 
lactoferrin to decrease the cytokines responsible for tissue destruction while maintaining 
production of those essential for the generation of responses necessary for protection  
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Figure 3.5. Lactoferrin modulation of BMM cytokine production in response 
to MTB infection.  BMM were infected with MTB Erdman using a MOI of 1:1.  
100 µg/ml of bovine lactoferrin was added at the same time as infection or 3 hours 
after infection.  The levels of TNF-α, IL-6, IL-12p40, and TGF-β were measured 
in the filtered supernatants 24 and 72 hours after infection by ELISA.  Data are 
shown as the mean and SD.  *p<0.05, comparisons are to cells infected with MTB 
alone.  
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against mycobacteria.  Lactoferrin alone does not alter the proliferation of MTB within 
macrophages (Chapter 4).    
 
Discussion 
 MTB causes approximately 1.8 million deaths annually and infects nearly one-
third of the world’s population [203].  The number of cases of this disease continues to 
rise, possibly due to the emergence of multi-drug resistant organisms and HIV co-
infection [133].  The therapy for TB is complex, lengthy, and requires antibiotics that 
have significant side-effects, often resulting in poor compliance to treatment.  The World 
Health Organization’s directly observed therapy short-course (DOTS) program is 
effective, but puts a significant financial burden on the resource poor countries that are 
disproportionately impacted by TB.  Therefore, new agents that can shorten TB 
treatment are needed.  Agents with immunomodulatory functions, such as lactoferrin, are 
a novel approach to TB treatment in that they may be able to circumvent drug resistance.  
Additionally, lactoferrin’s ability to decrease immune-related pathology may enhance 
antibiotic penetration into tissue and augment the generation of immune responses that 
can kill latent bacilli [131, 133].  
 TDM is a highly immunostimulatory glycolipid synthesized by MTB.  Challenge 
with a single dose of TDM results in recruitment of immune cells to lung tissue 
accompanied by production of cytokines that are similar to those synthesized during 
natural TB infection [17, 110].  The data presented here demonstrate that mice treated 
with lactoferrin following challenge with TDM had decreased lung immunopathology at 
the height of the granulomatous response.  Alteration of granuloma structure has a 
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number of potential implications for the therapy of both active and latent TB.  MTB 
within granulomas convert to a state of non-replicating persistence that is characterized 
by changes in biochemical pathways and decreased replication [15, 131, 132].  
Antimicrobial agents require actively replicating bacilli for effectiveness and are 
therefore unable to kill the dormant MTB isolated within granulomas.  Additionally, it is 
hypothesized that decreasing lung immunopathology may enhance the penetration of 
antibiotics within infected tissue, thereby enabling a faster response to TB chemotherapy 
[15, 133].  Use of TB antibiotics in combination with immunomodulators has generated 
promising results in human clinical studies.  One clinical trial evaluated addition of the 
soluble TNF-α receptor etanercept to antibiotic therapy in HIV patients with TB; there 
was significantly lessened time to sputum culture conversion accompanied by improved 
chest x-rays in the patients given the combination of anti-TB agents and etanercept 
[135].  Another trial explored combining high-dose prednisolone with anti-TB agents in 
patients co-infected with HIV and TB [136].  Sputum culture conversion rate was 
significantly increased in patients treated with prednisolone, in comparison to antibiotics 
alone.  Use of lactoferrin in combination with TB therapy has numerous advantages over 
other immunomodulators in use because it does not suppress the immune system and has 
a proven safety record in a number of animal models and human studies [134, 138, 139, 
235, 236]. 
 A hypothesized mechanism for the reduction in lung pathology in lactoferrin 
treated mice is the increased synthesis of TGF-β and IL-10, cytokines that have essential 
roles in decreasing pathology due to the immune system [58].  It is possible that TH2 
cytokines may decrease protective immune responses to TB [131].  However, the 
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cytokines considered critical for host defense against TB, IFN-γ and TNF-α [46], were 
not significantly altered by treatment with lactoferrin.  IFN-γ is necessary for control of 
mycobacterial burden; an example of the importance of this cytokine is the severe 
mycobacterial infections that occur in patients deficient in IFN-γ signaling factors [237].  
TNF-α is necessary for initiation and maintenance of granulomas; deficiency of TNF-α 
results in reactivation of latent disease and severe necrotic pathology [15, 46, 238].  
Lactoferrin’s ability to generate an anti-inflammatory response simultaneously with pro-
inflammatory cytokine synthesis has been described in other studies [140].  For example, 
lactoferrin administered orally to rats in a model of colitis increased the Th2 cytokines 
IL-4 and IL-10 [186], in addition to decreased immune-mediated pathology in mouse 
LPS sepsis models [183, 239].  In comparison, lactoferrin increased the delayed-type 
hypersensitivity response to ovalbumin, BCG, and sheep red blood cells [170, 171, 228].  
Lactoferrin’s ability to produce pro-inflammatory and anti-inflammatory responses 
makes it an ideal immunomodulator for a number of inflammatory and infectious 
diseases. 
  We report that macrophages treated with lactoferrin and infected with MTB 
produced higher levels of TNF-α.  This is in marked contrast to the overall reduction in 
proinflammatory cytokines when the BMM where stimulated with TDM-coated 
microspheres and given lactoferrin.  This is possibly attributed to the fact that MTB 
produces a variety of immunostimulatory moieties in addition to TDM, such as ligands 
for the toll-like receptors, NOD-like receptors, and C-type lectins [123].  Of 
significance, these experiments found that lactoferrin alone did not alter MTB growth in 
BMMs.  However, lactoferrin does have an impact on the growth of MTB in 
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macrophages, but only if the macrophages are activated with IFN-γ in addition to 
lactoferrin treatment (Chapter 4). The data presented here on infected macrophages 
indicate the necessity to determine the impact of lactoferrin in MTB infection models.  
The TDM granuloma model mimics certain aspects of the immune responses 
observed in murine aerosol infections.  This model system is thus ideal for screening 
immunomodulatory agents that may alter TB-induced lung pathology.  These studies 
suggest that lactoferrin may decrease lung pathology in a TB granuloma model while 
maintaining protective immune responses.  Lactoferrin may thus have potential 
advantages as an adjuvant therapeutic in the treatment of TB. 
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Chapter Four 
Lactoferrin as a therapeutic to modulate Mycobacterium tuberculosis induced 
immunopathology 
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Introduction 
 Tuberculosis (TB) remains a significant global public health burden.  There are 
approximately 9.27 million new cases of this disease and nearly two million deaths each 
year [1].  Over 95% of drug-susceptible Mycobacterium tuberculosis (MTB) can be 
cured with a four-drug regimen of isoniazid, rifampin, pyrazinamide, and ethambutol for 
two months followed by four additional months of isoniazid and rifampin [2].  However, 
the lengthy, complex drug regimen required to treat TB is difficult to administer in the 
resource poor countries that TB disproportionately affects.  Furthermore, the efficacy of 
the available drug regimen is threatened by the emergence of multi-drug resistant strains 
[1].  The last major advancement in TB therapeutics was made when rifampin was 
introduced in the 1960s [7].  Thus, there is considerable need to develop novel agents for 
the treatment of TB. 
 Th1 responses are critical for host defense against MTB [46].  MTB infection 
begins with uncontrolled growth of the TB bacilli within macrophages.  An innate 
granuloma forms due to the accumulation alveolar and recruited systemic macrophages.  
Dendritic cell presentation of TB antigens to naive CD4+ T-cells in the presence of IL-
12 generates a Th1 immune response [240].  Interferon-gamma (IFN-γ) production by 
Th1 cells activates macrophages, resulting in phagosome acidification, phagolysosome 
fusion, and synthesis of reactive nitrogen species that kill MTB [46].  CD4+ T-cells are 
also essential for the generation of CD8+ cytotoxic T-cells that may play a role in 
control of disease progression [46].  An example of the importance of the CD4+ T-cell 
response can be found in humans with advanced HIV, who develop disseminated 
mycobacterial infections when CD4+ T-cells reach low levels [45].  Additional immune 
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system responses are also likely important.  For example, a number of studies have 
highlighted the role of IL-17 in the immune response against MTB [64, 65, 241].  
Specifically, early enhancement of IL-17 responses by use of an IL-23 producing 
adenovirus during MTB infection resulted in decreased bacterial burden and reduced 
lung pathology [67].  Therefore, immunomodulatory agents useful in control of MTB 
infection are expected to produce a strong Th1 response, and perhaps IL-17 mediated 
responses. 
 Modulation of immune-mediated pathology while preserving essential immune 
responses may represent a novel therapeutic strategy for the treatment of TB.  The 
immunocompetant host responds to MTB infection by the formation of granulomas, 
which may prevent dissemination of the bacilli [17].  However, MTB within granulomas 
are protected from immune-mediated killing due to the sequestration of infected 
macrophages from immune effector cells [15].  MTB within granulomas adapt by 
conversion to a dormancy phenotype that includes decreased replication and changes in 
biochemical pathways, making the bacilli relatively resistant to the action of sterilizing 
antimicrobials [131, 132].  Furthermore, decreasing lung immunopathology may 
enhance antibiotic penetration in infected tissue, thus promoting a faster response to 
antimycobacterials [15, 133].  
 A number of studies suggest that lactoferrin has a number of immune modulating 
properties that may be favorable to the host during MTB infection [140].  Lactoferrin is 
an iron-binding glycoprotein member of the transferrin family that is found in mucosal 
secretions and neutrophil granules.  Specific effects of lactoferrin include macrophage 
activation, enhancement of phagocytosis, and enhancement of the delayed type 
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hypersensitivity response to a number of antigens [140].  Importantly, lactoferrin 
enhances Th1 immune responses in a number of model systems, a response essential for 
host defense against MTB [134, 140, 155, 157, 242, 243].  Critical to the studies 
proposed here, lactoferrin has been shown to protect against immune-mediated tissue 
damage.  For example, mice treated with lactoferrin had increased survival and 
decreased gut tissue destruction after LPS injection [183].  Additionally, lactoferrin 
added to the BCG vaccine resulted in increased protection against an aerosol TB 
challenge, with evidence of decreased lung damage [232].   
 These studies explored the ability of lactoferrin to modulate lung pathology 
during a mouse of MTB infection using a rapidly proliferating variant of MTB Erdman.  
We found that lactoferrin added to the drinking water during MTB infection decreased 
organ bacterial burden and lung immunopathology.  Lung immune responses were 
explored to determine the ability of lactoferrin to promote protective Th1 and IL-17 
mediated responses.   
 
Materials and methods 
Animals. Four week-old, female C57BL/6 mice were purchased from Jackson 
Laboratories.  All studies were conducted under the approval from the animal ethics 
committee at the UTHSC, protocol AWC-08-050.  Four to six mice were used per group, 
per time points indicated.  All MTB infections occurred in biosafety level 3 facilities. 
Lactoferrin and MTB.   Bovine-derived lactoferrin (15 – 20% iron saturated, <0.2 
endotoxin units/mg) was supplied by PharmaReview Corporation (Houston, TX).  A 
rapidly-proliferating variant of MTB Erdman (TMC 107, American Type Cell Culture) 
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was cultured in Middlebrook 7H9 broth with 10% supplement (5% bovine serum 
albumin, 2% dextrose, and 0.5% Tween 20 in distilled water) to log phase.  Pelleted 
bacteria were resuspended in phosphate buffered saline (PBS) and diluted to 3 x 108 
colony forming units (CFU) per ml using McFarland standards.  Bacteria were sonicated 
to disperse aggregates.  The bacterial CFUs were confirmed by plating serial dilutions on 
Middlebrook 7H11 agar plates (Remel, Lenexa, KS), which were incubated at 37 °C for 
3 – 4 weeks.      
Acute tuberculosis infection of mice.  MTB strain Erdman was cultured to log 
phase as described above.  C57BL/6 mice were infected using an aerosol inhalation 
exposure system (GLAS-COL Model #A4212 099c) to achieve an aerosol implantation 
of 100 CFUs.  The inoculation dose was confirmed by sacrificing a subset of mice at day 
one post-challenge, and the lung bacterial load determined by plating lung homogenates 
onto 7H11 agar plates.  The mice were randomized to either untreated controls or mice 
treated with lactoferrin at the start of infection to determine the effect of lactoferrin prior 
to development of histopathology, or beginning 7 days later to evaluate the impact of 
lactoferrin on established infection.  Lactoferrin was administered in the drinking water 
at 5 mg/ml to give a dose of approximately 20-25 mg per mouse, assuming mice drink 4-
5 ml of water per day [244], as was done in prior studies of oral lactoferrin-mediated 
immune modulation [180, 245].  Mice were sacrificed at 1, 2, and 3 weeks post-
infection.  The lung, spleen, and liver were aseptically removed, placed into 5 ml of 
PBS, and homogenized.  Serial dilutions of organ homogenates were plated onto 
Middlebrook 7H11 agar plates and incubated for 3 – 4 weeks at 37 °C.  
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Lung histopathology analysis.  Lung tissue was fixed in 10% formalin and 
embedded in paraffin.  Five µm thick sections were stained with hematoxilin and eosin 
by standard methods.  Acid-fast staining was performed by the Zhiel-Neelsen method.  
Twelve lungs from each group pooled from two different experiments at three weeks 
post-challenge were randomly selected for immunohistochemistry (IHC) for CD4 and 
CD8.  Rat anti-mouse monoclonal antibodies (R&D Systems, Minneapolis, MN) were 
used to detect CD4+ and CD8+ cells, with detection using an anti-rat horseradish 
peroxidase 3,3’diaminobenzidine cell and tissue staining kit according to the 
manufacturer’s instructions (R&D Systems). 
All images of histopathology were obtained with the Nuance multispectral 
imaging system (CRI, Woburn, MA).  This technology allows quantification of cell 
types in defined regions of pathology.  The entire region of the immunostained lungs 
was captured using the 10x objective.  Enumeration of normal lung, area percentages of 
macrophages and lymphocytes, and total number of CD4+ and CD8+ cells was done 
using the tissue and cell segmenting abilities of Inform software (CRI) as detailed by the 
manufacturer’s instructions.     
  Lung cytokine expression. Total lung RNA was isolated by homogenizing lung 
tissue in 1 ml of RNA-Bee (Tel-Test, Friendswood, TX), followed by addition of 0.1 ml 
of chloroform (Sigma).  The samples were mixed, incubated on ice for 15 min, and 
centrifuged for 15 min at 13,000 rpm.  The supernatants were removed and placed into 
an equal volume of isopropanol for overnight precipitation.  The samples were 
centrifuged at 13,000 rpm for 15 min.  The resulting RNA pellets were washed with 75% 
ethanol and resuspended in water with 1 mM EDTA.  cDNA was generated by mixing 2 
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µg of RNA into first strand buffer (Invitrogen,), 2.5 mM dNTPs (Invitrogen), 0.1 M 
DTT (Invitrogen), 80 U random hexamer (Roche Diagnostics, Mannheim, Germany), 
and 20 U RNAsin (Promega, Madison, WI).  The reaction mixture was heated to 70°C 
for 5 min, followed by addition of 200 U SuperScript II RT (Invitrogen).  The mixture 
was heated to 42°C for 50 min, and then 70°C for 15 min to terminate the reaction.   
 Analysis of cDNA was performed using the Taqman assay.  The sequences of 
primers and probes (FAM reporter and BHQ-1 quencher) for the cytokines are shown in 
Table 2.1.  The reaction mixture contained 5 µl cDNA, 1X PCR buffer (5Prime, Fisher 
Scientifics, Pittsburg, PA), 200 nM dNTPs (Invitrogen, Carlsbad, CA), 400 nM each for 
the forward and reverse primer (Integrated DNA Technologies, San Diego, CA), 100 nM 
probe (Biosearch Technologies, Novato, CA), 1x ROX reference dye (Invitrogen), and 1 
U/50 µl Taq DNA polymerase (Fisher).  The reaction was performed using the ABI 
Sequence Detection System (Applied Biosciences, Carlsbad, CA) by heating for 1 min at 
95 °C, and then 40 cycles of 95 °C for 12 seconds and 60 °C for 1 min.  Data are 
expressed as fold change expression relative to naive controls after normalization to β-
actin [202].   
 Preparation of lung digests and ELISpot analysis. Lung tissue from infected mice 
was removed, minced, and incubated at 37°C with 30 µg/ml DNAse (Roche Diagnostics, 
Mannheim, Germany) and 1 mg/ml type I collagenase (Worthington Biochemical 
Corporation, Lakewood, NJ) for 60 min on a rotating shaker.  The lung digests were 
passed through a 40 µm filter (Fisher) followed by centrifugation at 1500 rmp.  Red 
blood cells were lysed with ACK lysing buffer (Lonza, Walkersville, MD).  The cells 
were washed 2 times with PBS and counted using a hemacytometer.  One hundred µl of 
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lung digests or splenocytes (2 x 105 cells) (see above) were examined for IFN-γ and IL-
17 producing cells (eBioscience, San Diego, CA) and CD4+ IFN-γ cells (R&D Systems, 
Minneapolis, MN) according to the manufacturer’s instructions.  
 Recall response to MTB antigens.  Recall responses by splenocytes to heat-killed 
MTB was performed to evaluate lactoferrin modulation of the systemic immune 
response to MTB.  Spleens were harvested from infected mice at the times points 
designated above.  The tissues were minced using a glass homogenizer.  Red blood cells 
were lysed with ACK lysing buffer (Lonza), followed by washing twice with PBS.  
After counting with a hemacytometer, cells were resuspended in Dulbecco’s modified 
eagle’s medium (DMEM) (Sigma, St. Louis, MO) supplemented with 10% FBS, 0.01% 
HEPES (Sigma), and 0.01% L-arginine (Sigma).  Cells were plated into 24-well tissue 
culture plates at a concentration of 2 x 106 cells/ml.  Heat-killed MTB was added at a 
MOI of 10:1, generated by autoclaving MTB suspended in 1xPBS at 121°C for 10 mins.  
Subsets of cells were stimulated with 2 µg/ml conA or 10 ng/ml LPS as controls.  
Supernatants were collected at 72 hours post-stimulation, filtered with a 2 µm filter, and 
analyzed by ELISA for IL-17, IFN-γ, IL-10, IL-12p40, TNF-α, IL-6, and TGF-β (R&D 
Systems).  
 Proliferation of MTB in broth and macrophage culture in the presence of 
lactoferrin. MTB were grown in 7H9 broth alone, with 100 µg/ml lactoferrin, or with 1 
mg/ml of lactoferrin.  Bacteria were sonicated every 4 hours, the OD600 obtained, and 
serial dilutions plated on 7H11 agar plates.  The plates were incubated at 37 °C for 3 – 4 
weeks. 
 For macrophage proliferation studies, the J774A.1 (ATCC TIB-67) were cultured 
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in antibiotic-free DMEM with 2% FBS in 24-well tissue culture plates at a concentration 
of 5 x 105 cells/ml.  MTB Erdman were added at a MOI of 1:1.  Subsets of cells were 
given combinations of 10 ng/ml recombinant IFN-γ (Cell Sciences, Canton, MA), 100 
µg/ml lactoferrin, and 1 mM of the NO synthetase inhibitor N-mono-methyl-arginine 
(Sigma).  The cells were lysed every 48 hours with 0.05% SDS, neutralized with 15% 
bovine serum albumin (Sigma), and the lysates plated onto 7H11 agar plates.  The cell 
supernatants were also removed, filtered with a 0.2 µm filter and examined for IL-6, 
TNF-α, IL-12p40, and TGF-β production by ELISA (R&D Systems).  Production of NO 
was assessed by the Griess reaction as previously described [246].  Briefly, 50 µl of the 
culture supernatants were mixed with 50 µl of Griess reagent (1% sulfanilamide and 
0.1% naphthyl-ethylenediamine dihydrochloride in 1 N HCL).  The optical density at 
550 nm was determined.  NaNO2 was used to produce a standard curve. 
    
 Statistics.  The data are shown as the mean ± SD.  Two-way ANOVA was used to 
determine the differences between groups by use of GraphPad Prism software.  A p-
value of less than 0.05 was defined as statistically significant.  
 
Results 
Lactoferrin decreases bacterial burden in a mouse model of MTB infection 
 Acid-fast staining of lung tissue was performed by the Zhiel-Neelsen method 
(Figure 4.1A).  Control mice administered tap water had numerous acid-fast bacilli in the 
lung at three weeks post-challenge with a highly virulent variant of MTB Erdman.  
However, mice treated with lactoferrin had markedly fewer organisms visible on acid- 
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A. B. 
control 
LF at day 0 
Figure 4.1. Decreased organ bacterial burden in lactoferrin treated mice. A. 
Acid-fast staining in control mice three weeks post-infection demonstrates 
numerous acid-fast bacilli. A similar region of histopathology in mice given 
lactoferrin at day 0 shows markedly fewer bacteria.  B.  Mice treated with 
lactoferrin at day 0 had significantly reduced  bacterial burden in the lung at 
weeks 2 and 3 post-challenge, accompanied by decreased CFUs in the liver 
compared to mice given tap water.  Mice started on lactoferrin at day 7 had 
significantly decreased lung and liver CFUs at week 3.  Data are presented as the 
mean and SEM, n = 6 mice per group, per time point. *p < 0.05 with comparisons 
to control mice. 
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fast staining in regions with comparable histopathology.  Bacterial CFUs in the lung, 
liver, and spleen are shown in Figure 4.1B.  Specifically, control mice administered tap 
water had lung log10 CFUs of 2.5 ± 0.7 at week 1, 6.6 ± 0.9 at week 2, and 7.5 ± 0.3 at 
week 3.  In comparison, the mice treated with lactoferrin at the start of infection had 
significantly fewer lung CFUs at week 2 (5.0 ± 1.4) and week 3 (6.4 ± 0.7).  Mice 
treated with lactoferrin beginning at day 7 after established infection at day 7 had 
significantly reduced lung CFUs at week 3 (6.5 ± 0.4).  Bacterial growth in the spleen 
was not observed until week 2 and was not significantly different between the two 
groups.  Mice treated with lactoferrin at day 0 had significantly reduced liver CFUs at 
weeks 1 and 3 compared to control mice.  Mice given lactoferrin at day 7 had 
significantly decreased liver bacterial loads only at week 3. 
 
Lactoferrin reduces MTB induced lung immunopathology 
 Representative images of lung histopathology at three weeks post-challenge using 
hematoxylin and eosin staining are shown in Figure 4.2.  Control mice given tap water 
have severe inflammation with nearly complete lung occlusion and large areas of 
pulmonary edema (Table 4.1 and Figure 4.2A).  High power images demonstrate a 
predominance of macrophages, cellular debris, and tissue beginning to undergo necrosis 
(Figure 4.2B).  Few areas of lymphocytes were observed, with relatively few CD4+ and 
CD8+ cells visualized with IHC (Table 4.1). 
 In contrast, mice treated with lactoferrin had significantly reduced lung occlusion 
compared to control mice (Figure 4.2C and Table 4.1).  There was significantly  
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A. B. 
C. D. 
40x 400x 
Figure 4.2.  Histopathology in control (A & B) and lactoferrin treated 
mice beginning at day 0 (C & D) at three weeks post-infection.  A. 
Control mice demonstrate nearly complete lung occlusion, 40X.  B. High 
power image from control mice shows large numbers of macrophages, 
edema, and cellular debris, 400X.  C.  Mice treated with lactoferrin have 
significantly less areas of inflammation and occlusion, 40X.  D.  Mice 
treated with lactoferrin have clusters of lymphocytes, fewer areas of foamy 
macrophages, and less edema, 400X.  n = 6 mice per group. 
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Table 4.1.  Lactoferrin decreases lung immunopathology during MTB infection 
* p< 0.05 compared to control mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control LF at day 0 LF at day 7
!"#$%&"'((#$)*'% +,-."/".-+ 012-3"/"3-4 01,-4"/"2-+
!"56(7'896&:) 1,-;"/"22-; 0<<-4"/"23-+ 0;=-<"/"+-<
!"#>589'(>?:) .-2"/";-3 0==-3"/"1-. 0=;-,"/"+-2
@A.B"#>589'(>?:) 21;-<"/"=,=-3 02.=;-4"/";+,-4 02+.<"/";22-2
@A+B"#>589'(>?:) <4-4"/"=1-< 0<1,-="/"=<1-< 0;,+-+"/".++-<
 83 
decreased overall lung inflammation, less pulmonary edema and occluded vasculature, 
and reduced areas of macrophages in mice started on lactoferrin at day 0 and day 7 post-
infection.  Clusters of lymphocytes were frequently observed (Figure 4.2D).  The 
majority of the lymphocytes were CD4+ cells; abundant CD8+ cells were observed as 
well. 
 
Lactoferrin enhances IFN-γ mediated killing of MTB and modulates cytokine production 
in macrophage culture 
 Studies were undertaken to determine if lactoferrin has a direct effect on MTB 
proliferation.  The results of lactoferrin’s effect on MTB growth in broth culture are 
shown in Figure 4.3A.  A physiologic concentration of lactoferrin (100 µg/ml) did not 
alter the growth of MTB in 7H9 broth using either the OD600 or CFUs.  Only a very 
high, non-physiologic concentration (1mg/ml) had a slight inhibitory effect on MTB 
growth, possibly due to iron sequestration.  
 MTB proliferation with or without lactoferrin in macrophage culture was also 
assessed (Figure 4.3B).  Lactoferrin alone did not affect MTB growth in naive J774 
cells.  However, there was enhanced early killing when lactoferrin was used in 
combination with IFN-γ.  This effect is possibly mediated by NO, as macrophages given 
the combination of lactoferrin and IFN-γ produced significantly more NO compared to 
control and activated macrophages (Figure 4.4A).  The addition of the NO synthetase 
inhibitor N-mono-methyl-arginine abolished the enhanced MTB killing effect of 
lactoferrin and IFN-γ (Figure 4.4B).  
        Lactoferrin modulated cytokine production from infected macrophages  
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A. 
B. 
OD600 CFUs 
Figure 4.3.  MTB proliferation in broth and macrophage culture in the 
presence of lactoferrin.  A.  MTB were grown in 7H9 broth alone, with 100 
µg/ml lactoferrin, or 1 mg/ml lactoferrin. The OD600 values and bacterial CFUs 
both show that physiologic concentrations of lactoferrin (100 µg/ml) do not alter 
MTB growth.  Only very high, non-physiologic concentrations of lactoferrin 
have a slight impact of MTB growth.  B.  J774 macrophages were cultured in 
DMEM, infected with MTB at a MOI of 1:1, and treated with various 
combinations of lactoferrin and IFN-γ.  Lactoferrin alone did not impact MTB 
proliferation in macrophages.  However, there was enhanced early killing by the 
combination of lactoferrin and IFN-γ. 
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Figure 4.4.  Lactoferrin enhances IFN-γ mediated NO production.  
A. NO production was measured in the supernatants from infected J774 
cells using the Griess reaction.  Macrophages treated with the 
combination of lactoferrin and IFN-γ had markedly enhanced NO 
production. * p < 0.05, with comparison to control macrophages.  ** p 
< 0.05 with comparison to control macrophages activated with IFN-γ.  
B. Macrophages were treated with 1mM of the nitric oxide synthase 
inhibitor n-monomethyl-l-arginine (NMMA) with various 
combinations of 100 µg/ml lactoferrin (LF) and 10 ng/ml IFN-γ. 
A. 
B. 
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Figure 4.5.  Lactoferrin modulates cytokine production by 
infected macrophages.  J774 cells were cultured in DMEM, 
infected with MTB at a MOI of 1:1, and treated with various 
combinations of lactoferrin and IFN-γ.  Supernatants were collected 
at the indicated time points, filtered with a 0.2 µm filter, and 
analyzed for TNF-α, IL-6, IL-12p40, and TGF-β by ELISA.  * p < 
0.05 with comparisons to control macrophages. 
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(Figure 4.5).  There was significantly increased TNF-α production when lactoferrin was 
added to macrophages activated with IFN-γ.  Of potential importance, lactoferrin 
significantly increased IL-12p40 production, a cytokine of critical importance for the 
induction of Th1 responses [162, 163].  TGF-β synthesis was also significantly 
increased, a cytokine that has a number of regulatory functions [247].     
 
Lactoferrin modulates lung cytokine expression in MTB infected mice 
 Lung cytokine expression of TNF-α, IL-6, IL-12p40, TGF-β, IL-10, IFN-γ, and 
IL-17 was evaluated by Taqman qPCR (Figures 4.6 and 4.7).  Control mice increased 
expression of all cytokines over the three-week time course, with the exception of IL-
12p40 expression that peaked at week 2.  Lactoferrin administered both at day 0 and day 
7 post-challenge significantly decreased expression of the proinflammatory cytokine IL-
6.  IL-10, a cytokine with inhibitory actions on cell-mediated immunity, was also 
decreased by lactoferrin treatment.  There was a non-significant trend towards increased 
IFN-γ expression in the lactoferrin treated mice.  IL-17 expression was significantly 
increased by lactoferrin treatment.  There were no significant differences in lung 
expression of TNF-α, IL-12p40, or TGF-β between control and lactoferrin treated mice.     
 
Increased Th1 and IL-17 producing cells in the lung and spleens of lactoferrin treated 
mice 
 Lung and spleen homogenates were examined for IFN-γ, and for CD4+ IFN-γ 
producing cells by ELISpot analysis (Figure 4.8).  The levels of IFN-γ producing cells in  
 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.  Lung expression of proinflammatory mediators in MTB-
infected mice treated with lactoferrin.  Expression of TNF-α, IL-6, and 
IL-12p40 mRNA was quantified in the lung in mice challenged with MTB 
and treated with or without lactoferrin.  Data are expressed as fold change 
relative to naïve mice after normalization to β-actin.  Data are presented as 
the mean with SD, n = 6 mice per group, per time point.  * p < 0.05, 
comparisons are made to control mice. 
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Figure 4.7.  Lung expression of cytokines in MTB-infected mice 
treated with lactoferrin.  Expression of TGF-β, IL-10, IFN-γ, and IL-
17 was quantified in the lung in mice challenged with MTB and treated 
with lactoferrin.  Data are expressed as fold change relative to naïve 
mice after normalization to β-actin.  Data are presented as the mean with 
SD, n = 6 mice per group, per time point.  * p < 0.05, with comparisons 
to control mice. 
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Figure 4.8.  IFN-γ and CD4+ IFN-γ producing cells in the lung and 
spleen in control and lactoferrin treated mice.  Lung and spleen 
homogenates were incubated with heat-killed MTB for 48 hours.  Cells 
producing IFN-γ and CD4+ IFN-γ+ cells were enumerated by ELISpot 
analysis.  Comparisons made to control mice, n = 4 mice per group per 
time point.  * p < 0.05 
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the lung increased over the three-week time course in all groups examined.  The number 
of lung IFN-γ synthesizing cells became significantly greater at week 3 in both 
lactoferrin treatment groups compared to control mice.  The absolute numbers of IFN-γ  
producing cells in the spleen peaked at week 2 in all treatment groups.  Splenocytes had 
a higher number of IFN-γ producing cells at week 2 post-MTB challenge in the 
lactoferrin treated mice compared to control mice.  To determine if these IFN-γ 
synthesizing cells were Th1 cells, the lung and spleen digests were plated onto an 
ELISpot plate specific for CD4+ IFN-γ cells.  The numbers of CD4+ IFN-γ+ cells in the 
lungs were increased at week 3 in all groups examined, but significantly greater in the 
lactoferrin treatment groups.  CD4+ IFN-γ+ cells in the spleen were not significantly 
different between the groups.      
 IL-17 producing cells in the lung and spleen were also evaluated (Figure 4.9).  The 
total number of IL-17+ cells increased in the lungs over the three-week observation 
period.  There were significantly increased levels of IL-17 producing cells in the lung at 
week 2 in the lactoferrin treated mice.  The spleen had relatively few IL-17 producing 
cells, with no significant differences between the groups.   
 
MTB-specific responses by splenocytes are altered by lactoferrin treatment 
 Splenocytes from control and lactoferrin treated mice were isolated and stimulated 
with heat-killed MTB for 72 hours.  Supernatant TNF-α, IL-6, IL-12p40, TGF-β, IL-10, 
IFN-γ, and IL-17 levels are shown in Figures 4.10 and 4.11.  Splenocytes from both 
lactoferrin treatment groups had significantly elevated IL-12p40 at week 2 and IFN-γ at  
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Figure 4.9.  IL-17 producing cells in the lung and spleen in control 
and lactoferrin treated mice.  Lung and spleen homogenates were 
incubated with heat-killed MTB for 48 hours.  IL-17 producing cells 
were enumerated by ELISpot analysis.  Comparisons are made to control 
mice, n = 4 mice per group per time point.  * p < 0.05 
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Figure 4.10.  Specific protein production of proinflammatory 
mediators from control and lactoferrin treated mice.  Splenocytes 
from control and lactoferrin treated mice were stimulated with heat-kill 
MTB for 72 hours.  TNF-α, IL-6, and IL-12p40 were measured in the 
supernatants by ELISA.  Comparisons are made to control mice.  Data are 
presented as the mean with SD, n = 4 mice per group per time point. * p < 
0.05 
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Figure 4.11.  Specific protein production of cytokines from control and 
lactoferrin treated mice.  Splenocytes from control and lactoferrin treated 
mice were stimulated with heat-kill MTB for 72 hours.  TGF-β, IL-10, 
IFN-γ, and IL-17 were measured in the supernatants by ELISA.  
Comparisons are made to control mice.  Data are presented as the mean 
with SD, n = 4 mice per group per time point. * p < 0.05 
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week 3.  The mice given lactoferrin at day 7 after infection had increased TNF-α and IL-
10 at week 3, and increased IFN-γ recall response at week 2.  Both lactoferrin treatment 
groups had decreased IL-17 splenocyte synthesis at week 2.  There were no differences 
in splenocyte synthesis of IL-6 or TGF-β in response to heat-killed MTB. 
 
Discussion 
 TB continues to be a major cause of morbidity and mortality due to infectious 
diseases.  Treatment of this disease requires 6 – 9 months of anti-TB chemotherapy that 
is difficult to administer in the regions of the world that have the highest burden of TB 
cases.  Thus, there is a considerable need to develop novel agents for the treatment of TB 
both to shorten the treatment time and combat the emergence of drug resistant 
organisms.  Increasing evidence suggests that immune modulating therapies that target 
granulomas and enhance protective immune responses may be useful as adjunct 
therapeutics for the treatment of TB [15].    
 Lactoferrin treated mice demonstrated a decrease in lung bacterial CFUs and a 
reduction in bacterial dissemination to the liver.  These favorable effects were evident 
even when the mice were treated one week post-infection, indicating that lactoferrin has 
the potential as a novel agent for the treatment of TB.  This decrease in bacterial burden 
is not likely due to a direct effect of lactoferrin on MTB because physiologic 
concentrations of lactoferrin did not alter MTB proliferation in either broth or 
macrophage culture.  Thus, we hypothesize that the mechanism of bacterial reduction is 
due to immune modulation.  Indeed, mice treated with lactoferrin had higher numbers of 
Th1 cells in the lung at three weeks after infection.  Lactoferrin has been shown to 
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increase cell-mediated immune responses in a number of infectious disease models 
[140].  Enhancement of antigen presenting cell activity is one potential mechanism by 
which lactoferrin may promote Th1 responses.  Lactoferrin increased expression of 
MHC II and the CD86:CD80 ratio in BCG-infected macrophages and dendritic cells, and 
resulted in increased production of IFN-γ from overlaid CD3+ and CD4+ cells compared 
to cells cultured without lactoferrin [155-157].  Lactoferrin may also enhance Th1 
responses by modulation of antigen presenting cell cytokine production.  Lactoferrin was 
demonstrated to increase production of IL-12 in a number of studies [155-157, 164, 
228], including the data presented here.  IL-12 is an essential cytokine for induction of 
IFN-γ from naive T-cells and enhancing production from mature Th1 cells [162, 163].  
Furthermore, lactoferrin appeared to enhance IFN-γ mediated bacterial killing in 
macrophage culture; this effect is possibly due to enhancement of NO production.  Other 
studies have reported increased NO production by lactoferrin, both in macrophage 
culture and in vivo [231, 248].  IFN-γ induced NO synthesis by macrophages is 
considered a crucial antimycobacterial activity [249].  Thus, we hypothesize that a major 
mechanism of lactoferrin’s favorable effect during MTB infection is the generation of 
IFN-γ producing cells; IFN-γ in turn acts synergistically with lactoferrin to enhance 
macrophage killing of MTB, possibly through NO production.    
 Lactoferrin increased IL-17 producing cells in the lung in addition to 
enhancement of IFN-γ mediated responses.  To our knowledge, this is the first report of 
lactoferrin modulation of IL-17 responses.  Several studies suggest that IL-17 
synthesizing cells may play an important role in MTB host defense [64, 65, 241].  Early 
enhancement of IL-17 responses by use of an IL-23 producing adenovirus during MTB 
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infection resulted in decreased bacterial burden and reduced lung pathology [67].  Thus, 
an early increase in IL-17 responses in the lactoferrin treated mice may have contributed 
to the reduction in bacterial CFUs and lung histopathology.  The mechanisms by which 
IL-17 may be protective during MTB challenge include augmentation of bacterial killing 
by enhancement of IFN-γ responses that activate macrophages, direct stimulation of 
phagocytic cells, recruitment of neutrophils, and increasing expression of antimicrobial 
peptides that have activity against MTB [67, 250].    
Mice treated with lactoferrin had a marked reduction in lung immunopathology 
in addition to a decrease in bacterial CFUs.  Modulation of MTB-induced inflammatory 
pathology has been proposed as a mechanism to decrease the treatment time for TB [15], 
an approach successfully used in animal studies and human clinical trials.  For example, 
the TNF-α reducer thalidomide used in combination with anti-TB antibiotics reduced 
mortality, brain pathology, and leukocytosis in a rabbit model of TB meningitis 
compared to anti-TB chemotherapy alone [251].  A clinical trial exploring the 
combination of etanercept, a soluble TNF-α receptor, with TB antibiotics in patients co-
infected with HIV and TB reported increased bacterial clearance and improved chest-
rays with the combination therapy [135].  A second clinical trial in individuals with HIV 
and TB demonstrated a higher rate of sputum culture conversion when high dose 
prednisolone was used as the immunomodulator in conjunction with TB antimicrobial 
chemotherapy [136].  In addition to an overall reduction in lung pathology, lactoferrin-
treated mice had a decreased percentage of macrophages, an increased percentage of 
lymphocytes, and increased numbers of CD4+ and CD8+ cells, suggesting an increase in 
immune cells with protective effects during MTB infection.  
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In light of the increased emergence of drug resistant organisms and the 
increasing incidence of TB, it is essential to develop new agents for the treatment of TB.  
It is noteworthy that lactoferrin reduced bacterial burden, accompanied by an increase in 
certain proinflammatory responses while decreasing overall lung immunopathology.  
Lactoferrin has a number of advantages over the current immunomodulators in use 
because it does not suppress the immune system and has a proven safety record in a 
number of animal models and human clinical trials [138, 139, 235, 236]. These 
investigations indicate that lactoferrin has potential as a novel therapeutic for the 
treatment of TB.      
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A major focus of this thesis centered on investigations into the molecular control 
of the granulomatous response to mycobacterial cord factor trehalose-6’6-dimycolate 
(TDM).  The granuloma is the histopathologic hallmark of Mycobacterium tuberculosis 
(MTB) infection.  The tuberculosis (TB) bacilli are likely recognized by alveolar 
macrophages following inhalation of the organism [17].  These macrophages secrete 
cytokines and chemokines that recruit monocytes from systemic circulation and form the 
innate granuloma.  At some point after infection, a dendritic cell becomes infected or 
processes MTB antigen and migrates to the draining lymph node of the lung.  Dendritic 
cell presentation of MTB antigen to naive T-cells generates adaptive immune responses.  
Antigen-specific T-cells migrate to the lung and surround infected macrophages, 
generating mature granulomas [17].  
Granuloma formation is often considered a “double-edged sword” in the host 
defense against MTB [15].  Granuloma formation is clearly needed to prevent 
uncontrolled infection and bacterial dissemination, as demonstrated in both animal and 
studies where factors essential for granuloma generation and maintenance are 
dysregulated [190, 204, 207].  However, there is increasing evidence that MTB possess 
certain factors that specifically drive granuloma formation and tissue remodeling that 
results in physical sequestration of the bacilli from effector immune cells capable of 
killing the organism [15].  Specifically, MTB has been shown to directly interfere with 
intracellular signaling to drive granuloma formation.  A MTB mutant lacking the 
adenylate cyclase Rv0386 was characterized by reduced cAMP after infection, 
accompanied by decreased protein kinase A and CREB activation, and ultimately 
decreased TNF-α synthesis by infected macrophages [104].  The mutant MTB had poor 
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survival in a mouse infection model and decreased lung pathology.  MTB also possess 
mycolic acids, such as trehalose dimycolate, that have been shown to drive granuloma 
formation [13, 116, 118].  Thus, an understanding of the immunological factors that 
drive granuloma formation may lead to novel targets for the treatment of tuberculosis.  A 
portion of this thesis specifically explores the role of TNF-α, complement factor C5a, 
and IL-6 in the generation and maintenance of TDM induced granulomas. 
The TDM model of granuloma formation mimics certain aspects of MTB 
induced immunopathology and is ideal for studying the immunologic factors necessary 
for early granuloma formation [13, 116, 118, 119, 130].  The investigations presented in 
this thesis demonstrate that TNF-α is a key cytokine in mycobacterial TDM induced 
granulomas.  TNF-α deficient mice challenged with intravenous TDM prepared in 
emulsion form failed to generate a histological response to TDM, accompanied by an 
absence of proinflammatory mediators and chemokines.  Macrophages are the innate cell 
type that responds to TDM [122] and are likely the source of TNF-α during the initial 
immune response to MTB [252].  TNF-α possibly acts by inducing chemokines during 
early infection that facilitate recruitment of other immune system cells [191].  Studies 
performed on animal models of MTB infection indicate that TNF-α is clearly involved 
in the maintenance of established granulomas because treatment with a TNF-α 
neutralizing antibody disrupts chronic granulomas [190], but this phenomenon could not 
be evaluated in the TDM granuloma model.  Use of TNF-α neutralizing therapy in 
patients latently infected with MTB resulted in reactivation of latent infection, often 
accompanied by extrapulmonary disease [204].  Inhibition of TNF-α during TB 
chemotherapy has been proposed as a novel therapeutic strategy because neutralization 
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of TNF-α has been shown to convert MTB from a state of non-replicating persistence to 
active replication, thus making the bacteria susceptible to antibiotics [15].  This 
approach was successful in both an animal model and a human clinical trial [135, 251], 
indicating that TNF-α may be a useful target employed during antimycobacterial 
chemotherapy.   
The studies in this thesis also demonstrate that complement factor C5a plays a 
role in the generation of cohesive granulomas to TDM.  C5a -/- mice developed severe 
pathology accompanied by reduced early synthesis of proinflammatory mediators and an 
absence of IL-12.  Complement C5a is a potent anaphylatoxin that recruits cells to the 
sites of active inflammation [87].  Thus, it is intriguing that deficiency of a chemotactic 
factor resulted in increased influx of cells that produced less inflammatory cytokines.  
C5a is necessary for NFκB activation, an expression regulator for a variety of 
inflammatory mediators, thus possibly accounting for the delayed expression of 
proinflammatory mediators [215].  Furthermore, C5a induces macrophage adhesion 
molecule expression [216, 217], possibly accounting for the inability of C5a-/- mice to 
form cohesive cellular aggregates.  The inability of complement deficient animals to 
produce IL-12 has been documented in a number of other investigation, but a precise 
mechanism has yet to be defined [88].  A number of studies have indicated that the 
decreased IL-12 production by complement deficient animals results in defective cell-
mediated immunity [92, 212, 253].  However, studies in humans have not demonstrated 
an increased susceptibility to TB in patients deficient in complement components; in 
fact, it has been suggested that such patients may be less susceptible to TB because of 
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reduced opsonization and phagocytosis [254].  Therefore, the role of the complement 
system in TB infection and as a therapeutic target remains to be determined.   
IL-6 also appears to play a role in TDM induced granulomas.  Mice deficient in 
this cytokine initially formed granulomas, but failed to maintain them and had severe, 
edematous inflammation.  The IL-6 -/- mice had decreased early production of 
proinflammatory mediators, similar to the complement deficient mice.  An investigation 
by Clahsen and Schaper [255] demonstrated that IL-6 promoted activation of β1-integrin 
and cellular migration across endothelial cells, suggesting that IL-6 has chemokine-like 
properties.  It is hypothesized that IL-6 from macrophages may thus be needed to 
maintain a coordinated response to mycobacterial antigens.  Additionally, a recent 
investigation demonstrated that IL-6 is necessary for regulating local concentrations of 
glucocorticoids that modulate pathological responses [219].  The TDM model used in 
these experiments explores early, innate immune responses.  Thus, the role of IL-6 in 
chronic TB infection cannot be determined from these studies.  Long-term studies of the 
role of IL-6 using MTB infection have generated mixed results.  An intravenous 
challenge of 106 MTB was lethal for IL-6 -/- mice in one study [107];  however, a low 
dose aerosol challenge of IL-6 deficient mice in a different investigation had reduced 
IFN-γ production but ultimately contained the infection [105].  The role of IL-6 in 
human TB infection is less clear.  To date, there have been no studies that link IL-6 
polymorphisms or disruption of IL-6 to TB susceptibility [256].  Therefore, the role of 
IL-6 as a therapeutic target for TB treatment remains to be clarified. 
The overall hypothesis from our studies on the cytokine mechanisms of TDM-
induced granuloma formation is that TNF-α is essential for the initiation of an 
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inflammatory response to TDM, possibly by inducing chemokines needed to recruit cells 
to the lungs.  Once a response has been initiated, complement C5a and IL-6 recruit cells 
that produce regulating cytokines and upregulate integrin that allow cells to form 
organized, cohesive structures.  Such studies may provide insight on the implications of 
using cytokine inhibitors to treat patients with chronic inflammatory disorders who may 
have latent TB disease as well as provide targets for the treatment of TB.    
Granulomas are clearly essential in the prevention of uncontrolled bacterial 
proliferation and dissemination.  However, it is hypothesized that modulation of 
granuloma structure may be a novel target for the treatment of TB [15].  MTB 
sequestered within granulomas enter a state of non-replicating persistence characterized 
by absent bacterial division and the use of altered biosynthetic pathways [131, 132], thus 
rendering the bacteria relatively resistant to the action of antibiotics.  The physical 
structure of the TB granuloma is such that killer lymphocytes capable of lysing infected 
cells are physically separated from the infected cells by a layer of fibrosis [17].  Finally, 
reducing the inflammatory pathology induced by MTB may enhance antibiotic 
penetration into tissues.  Reduction of pathology has led to favorable results in both 
animal and human studies [135, 136, 251].  Therefore, studies were undertaken to 
develop a therapeutic to reduce the pathological response to MTB and its antigens.   
Lactoferrin was selected the candidate immune modulator for these studies 
because it has been shown to reduce immune mediated tissue destruction in a variety of 
inflammatory and infectious disease models.  For example, lactoferrin added to the BCG 
vaccine as an adjuvant resulted in both increased protection following challenge with 
virulent MTB and decreased lung occlusion [232].  Additionally, mice injected with LPS 
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and treated with lactoferrin had decreased mortality and reduced gut tissue destruction 
[183].  Therefore, studies were conducted to determine if lactoferrin is able to modulate 
the immune response to mycobacterial antigens using TDM.   
Macrophages were first stimulated with TDM-coated beads and lactoferrin added 
to the culture media; lactoferrin treatment of the macrophages resulted in globally 
reduced proinflammatory cytokine production.  Mice challenged intravenously with 
TDM and treated with 24 hours later had significantly fewer and smaller granulomas at 
the peak of the granulomatous response.  Overall, proinflammatory cytokine production 
in the lungs of TDM-challenged mice was not significantly altered by lactoferrin; 
however, TGF-β and IL-10, cytokines that can have anti-inflammatory functions, were 
increased in lactoferrin treated mice.  When macrophages were infected with MTB and 
treated with lactoferrin, production of certain proinflammatory cytokines were increased.  
It is hypothesized that lactoferrin modulated macrophage cytokine production in vivo to 
reduce the histopathological response to TDM.  However, it is intriguing that different 
cytokine responses were obtained when lactoferrin was added to macrophages 
stimulated with TDM-coated microspheres, mice challenged with TDM, and 
macrophages infected with MTB.  Lactoferrin is known to have different effects 
depending on the model system, the inflammatory stimulus, and the immune status of 
the host [140].  For example, lactoferrin treated macrophages stimulated with a low dose 
of LPS had increased production of proinflammatory cytokines compared to untreated 
cells [175].  However, macrophages given higher doses of LPS had reduced 
proinflammatory cytokine production when lactoferrin was added to the culture media.  
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This unique property of lactoferrin makes it an ideal candidate immunomodulator for a 
number of inflammatory and infectious diseases. 
The differing cytokine production when macrophages are given isolated TDM 
and live mycobacteria suggested that in vivo infection with MTB would likely give 
different results than those obtained from the TDM model.  Additionally, the TDM 
model used in these studies only allows exploration of innate responses.  Cell-mediated 
immunity is critical to the control of TB infection, which cannot be evaluated in the two-
week TDM model.  Furthermore, the alteration of granuloma structure and production of 
cytokines with anti-inflammatory properties may result in enhanced bacterial 
dissemination from the lung [131], a phenomenon that cannot be evaluated using the 
TDM model.  Therefore, mice were aerosol challenged with a low dose of MTB strain 
Erdman and treated with lactoferrin by adding it to the drinking water.  We found that 
mice treated with lactoferrin at the start of infection or one week after infection had 
decreased organ bacterial burden.  Furthermore, lactoferrin treated mice had decreased 
lung histopathology, fewer areas of foamy macrophages, and increased numbers of 
lymphocytes.  The fact that lactoferrin had a favorable effect even when given after 
established infection indicates that lactoferrin has the potential to be a novel therapeutic 
for the treatment of TB.  
The hypothesized mechanism of lactoferrin-mediated reduction in bacterial 
burden is the early induction of Th1 immune responses.  Th1 cells produce IFN-γ, which 
in turn acts synergistically with lactoferrin to augment nitric oxide mediated killing of 
MTB by macrophages (Figure 5.1).  A number of other investigations have reported that 
lactoferrin increases Th1 responses.  For example, lactoferrin administered orally  
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Figure 5.1.  Hypothesized mechanism for the reduction in MTB bacterial 
burden by lactoferrin treatment.  Innate antigen presenting cells present 
MTB antigen to naive T-cells on MHC II. Lactoferrin augments the induction 
of Th1 cells by increasing IL-12 production, as well as increasing expression 
of MHC II and the costimulatory molecules CD40 and CD86. IFN-γ 
production by Th1 cells acts synergistically with lactoferrin to promote MTB 
killing by macrophages in a nitric oxide dependent manner.  
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increased Th1 responses, indicated by increased IFN-γ production, in both naive and 
tumor-harboring mice [173, 174].  Transgenic mice expressing human lactoferrin and 
infected with Staphylococcus aureus had increased IFN-γ and TNF-α, along with 
decreased IL-10 and IL-5 [172].  The possible mechanism by which lactoferrin increases 
Th1 responses is enhancement of innate immune cell antigen presentation and increased 
production of IL-12 [140].  While lactoferrin increased Th1 responses in the studies 
presented here, others have reported that lactoferrin can increase Th2 responses 
depending on the model system.  For example, lactoferrin increased IL-10 and decreased 
IFN-γ in an infection model of Toxoplasma gondii, indicating the enhancement of Th2 
responses [177].  The precise mechanisms by which lactoferrin promotes Th1 versus 
Th2 responses is unknown; however, this ability of lactoferrin gives it the potential to be 
beneficial in a number of disease states.   
Lactoferrin treatment also increased the numbers of IL-17 producing cells in the 
lungs of MTB infected mice.  To our knowledge, this is the first report of lactoferrin 
affecting levels of IL-17+ cells.  New evidence suggests that IL-17 producing cells play 
an important role in the host defense against MTB [64, 65, 241].  Of importance to these 
studies, early enhancement of IL-17 responses by administration of an IL-23 producing 
adenovirus during infection with MTB reduced lung bacterial burden and pathology 
[67].  Thus, the early appearance of IL-17 producing cells in the lactoferrin treated mice 
may have contributed to the reduced pathology and bacterial burden.  Potential 
mechanisms by which IL-17 may be protective during MTB infection include 
enhancement of IFN-γ responses that activate macrophages, neutrophil recruitment, 
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stimulation of phagocytic cells, and increasing expression of antimicrobial peptides with 
activity against MTB [67, 250].  
While a number of receptors for lactoferrin have been reported [141], the precise 
intracellular signaling mechanisms induced after activation by lactoferrin remain 
undefined.  A 105-kDa lactoferrin receptor is found on platelets and lymphocytes and 
possibly initiates signaling cascades [166, 257].  Lactoferrin was shown to bind surface 
nucleolin, followed by endocytosis, and translocation of the lactoferrin/nucleolin 
complex to the nucleus [258].  Other lactoferrin receptors are the low-density lipoprotein 
receptor related proteins (LRPs) that are found on a number of cell types including 
macrophages [141].  Finally, an intestinal receptor that induces lactoferrin endocytosis is 
hypothesized to promote IL-18 synthesis and increase in systemic Th1 responses [259].  
How lactoferrin promotes different immune responses is likely dependent on the model 
system under investigation.    
The ability of lactoferrin to have a favorable effect during MTB infection when it 
is administered orally increases its appeal as a therapeutic, especially in drug-resistant 
infections that require the administration of injectable medications.  However, it is not 
clear if lactoferrin’s effects were mediated by modulation of systemic immune responses 
or local action at the lung.  The decreased CD4+IFN-γ+ and IL-17+ cells in the spleen 
compared to the lung suggest that lactoferrin had different local and systemic responses.  
Lactoferrin undergoes partial digestion in the gastrointestinal tract to produce peptides, 
such as lactoferricin, that have antimicrobial effects [260].  The effects of specific 
lactoferrin peptides on MTB growth and immune modulation during MTB infection are 
currently unknown.  However, an investigation in humans reported that gastric survival 
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of lactoferrin is at least 60% [261].  Studies in mice demonstrate that intact lactoferrin 
accumulates in a number of organs shortly after oral administration [262].  A study using 
a peptide of human lactoferrin showed that it accumulates at sites of active inflammation 
in a mouse model of MRSA infection [263].  Thus, orally administered lactoferrin has 
the potential to modulate infection and inflammation in specific tissues.  
 Further increasing the appeal of lactoferrin is its favorable safety profile in a 
number of animal and clinical studies.  A major concern over the use of novel agents in 
the treatment of TB is that the long use required for treatment may result in toxicity.  
F344/DuCrj rats given bovine lactoferrin in their diet for 40 weeks had no clinical signs 
of toxicity and had significantly lower liver transaminases, blood urea nitrogen, and 
triglyceride levels compared to control rats [138].  A phase 2 clinical trial was conducted 
in patients with disseminated renal cell carcinoma who were given a recombinant form 
of human lactoferrin for 12 weeks reported good tolerability and no renal, hematologic, 
or hepatic toxicities [137].  No major toxicities were reported in a 12 week trial 
evaluating the impact of bovine lactoferrin on patients with chronic hepatitis C [139].  
Thus, lactoferrin represents a natural molecule that is well suited for clinical use. 
 
Future Directions 
 TB remains a major public health problem, accounting for approximately 2 
million deaths each year [1].  The studies presented in this thesis indicate that lactoferrin 
has the potential to be a novel therapeutic in the treatment of TB.  However, TB 
treatment requires the use of a combination of at least four drugs [2].  It is essential to 
confirm that lactoferrin still has a favorable effect when used in a combination drug 
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regimen.  It is theoretically possible that lactoferrin may antagonize the action of a 
specific antimycobacterial antibiotic.  Furthermore, such studies will determine if 
lactoferrin can be used in combination with standard TB drugs to generate novel drug 
regimens that will allow for shortening the time needed to treat TB.              
 To our knowledge, these studies are the first to report that lactoferrin increases 
production of IL-17.  Future studies can be performed to further characterize the 
importance of these responses.  For example, IL-17 knock-out mice (currently not 
commercially available) can be infected with MTB and treated with lactoferrin to 
determine if lactoferrin still has a favorable effect in the absence of IL-17.  Alternatively, 
wild-type mice can be treated with a neutralizing IL-17 antibody, but such experiments 
are extremely expensive.   
 Additionally, it is not known if lactoferrin acted systemically or locally in the 
lungs when either TDM-challenged or MTB-infected mice were treated with lactoferrin.  
Studies can be undertaken to label lactoferrin and determine its distribution in MTB 
infected mice.  Additionally, it is possible that lactoferrin peptides generated in the 
digestive tract of treated animals may be responsible for some of the effects observed.  
Thus, peptides of lactoferrin can be generated and tested for immune modulating activity 
and therapeutic potential during MTB treatment.   
 Finally, these experiments explored the utility of lactoferrin in an acute model of 
MTB.  Human patients are likely to present for treatment with chronic lesions.  It is 
unclear at this time if administration of lactoferrin to individuals with on-going chronic 
disease will alter pathology.  Experiments can be performed to determine if lactoferrin 
still has a favorable effect when administered to animals with established chronic 
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infection.  However, humans with active TB often have cavitary lesions.  Unfortunately, 
the animal models that adequately replicate the cavitary lesions that are found in human 
post-primary TB patients are not completely standardized [13]; it would be premature to 
investigate lactoferrin effects in these model systems until this obstacle if overcome.   
 In summary, these studies provide insights into the cytokine mechanisms by 
which mycobacterial antigens induce granulomas.  The lung immunopathology induced 
by trehalose-6’6-dimycolate can decreased by lactoferrin, possibly by modulation of 
macrophage cytokine production.  Finally, lactoferrin has a number of favorable effects 
during MTB infection including reduction of organ bacterial burden and lung 
inflammation.  The hypothesized mechanism by which lactoferrin decreases bacterial 
CFUs is by increasing Th1 responses and increased IFN-γ mediated killing by 
macrophages.  Thus, lactoferrin has the potential as a novel therapeutic for TB treatment.                            
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